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ABSTRACT 
A small library of 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones has been synthesized and 
screened according to protocols available at the National Cancer Institute (NCI). Some derivatives 
resulted potent antiproliferative agents, showing GI50 values in the nanomolar range. Remarkable, 
when most active compounds against leukemia cells were tested in human peripheral blood 
lymphocytes from healthy donors, resulted 100-200 times less cytotoxic. Some compounds, selected 
by the Biological Evaluation Committee of NCI, were examined to determine tubulin assembly 
inhibition. Furthermore, flow cytometric studies performed on HeLa, HT-29, and A549 cells, showed 
that compounds 14 and 25 caused a block in G2/M phase. Interestingly, these derivatives induced 
apoptosis through the mitochondrial death pathway, causing in parallel significant activation of both 
caspase-3 and -9, PARP cleavage and down-regulation of the anti-apoptotic proteins Bcl-2 and Mcl-
1. Finally, compound 25 was also tested in vivo in the murine BL6-B16 melanoma and E0771 breast 
cancer cells, causing in both cases a significant reduction of the tumor volume. 
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1. Introduction 
 Cancer represents a group of diseases which are among the leading causes of morbidity and 
mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths 
in 2012 (World Cancer Report 2014). Although considerable progresses in cancer survival has been 
obtained, particularly for hematopoietic and lymphoid malignancies, these impressive data 
demonstrate that the development of specific therapies remains an unmet need. Among current 
anticancer agents, microtubule-targeting molecules have a high therapeutic potential, since they 
suppress microtubule dynamics, generally causing cell cycle arrest at mitosis in prometaphase, 
followed by the activation of apoptosis. Anti-microtubule agents interact with tubulin through 
multiple binding sites. The most extensively studied are the vinca domain, the colchicine site and the 
α-taxane site [1]. Vinca alkaloids, such as vinblastine, vincristine, and vinorelbine, prevent tubulin 
polymerization by interacting with a binding site located between two tubulin dimers, interacting 
almost equally with the α-subunit of one dimer and the β-subunit of the other one. The colchicine site 
is located at the intradimeric αβ interface of tubulin heterodimers, but the primary interactions of 
colchicine are with β-tubulin amino acid residues [2]. Some compounds that inhibit colchicine 
binding to tubulin have more extensive interactions than does colchicine with α-tubulin residues at 
the dimer interface [3]. The binding site for taxanes and other chemotypes that inhibit [3H]paclitaxel 
interaction is on the inner surface of polymerized microtubules on the β-subunit. These compounds 
stabilize microtubule structure and prevents their disassembly.  
Despite a variety of antimitotic agents already used in anticancer therapy, drug resistance, toxicity 
and side effects remain problems to be solved, hence the development of new molecules interacting 
with microtubules still represents an attractive objective. In this field, our research group published a 
study concerning new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones, which 
were tested for inhibition of tubulin assembly [4]. Considering that the effects on tubulin assembly 
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were modest, compared to their cytotoxic activity, we planned the synthesis of a small library of new 
analogs, in order to improve the antiproliferative profile and to further study the mechanism of action. 
The new derivatives were obtained by condensing imidazothiazole aldehydes with oxindoles 
(Scheme 1, Table 1) through the Knoevenagel reaction. This permits the ready synthesis of adducts 
by reacting an aldehyde with an activated methylene group, thus allowing the generation of a large 
series of compounds. To create the library, the substituents on the synthons were chosen by taking 
into consideration the biological results obtained in our previous studies [4,5]. Since derivatives 
bearing a 2-pyridyl group at the 6 position of the imidazothiazole system showed significant 
antiproliferative activity, we investigated the effects of shifting the nitrogen in the pyridine system 
by substituting the 2-pyridyl group with a 3-pyridyl (compounds 3-14) or 4-pyridyl (compounds 15-
25) group. Good results were also obtained when the imidazothiazole nucleus was substituted at 
position 6 with a methoxy group, so a series of derivatives characterized by this feature and bearing 
the indolinone nucleus with different substituents was prepared (compounds 26-37). Finally, another 
imidazothiazole nucleus was introduced at the 6 position of the imidazothiazole system (38-52), in 
order to study the effects of this bulky heterocycle never used in previously synthesized derivatives. 
 
 
Scheme 1. Synthesis of the new 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones. 
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Table 1. New 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones derivatives and starting 
compounds 
Comp. Starting compound 1 Starting compound 2 
  R R1  R2 R3 R4 R5 R6 
3 1a H 
 
 
2a H H H H H 
4 1a H 
 
 
2b CH3 H H H H 
5 1a H 
 
 
2c H H OCH3 H H 
6 1a H 
 
 
2d CH3 H OCH3 H H 
7 1a H 
 
 
2e H H OH H H 
8 1a H 
 
 
2f CH3 H OH H H 
9 1a H 
 
 
2g H H OCH3 CH3 H 
10 1a H 
 
 
2h CH3 H OCH3 CH3 H 
11 1a H 
 
 
2i H H OH CH3 H 
12 1a H 
 
 
2j H H F H H 
13 1a H 
 
 
2k H H Cl H H 
14 1a H 
 
 
2l H H H CBR 
15 1b H 
 
 
2a H H H H H 
16 1b H 
 
 
2b CH3 H H H H 
17 1b H 
 
 
2c H H
 
OCH3 H H 
18 1b H 
 
 
2d CH3 H OCH3 H H 
19 1b H 
 
 
2e H H OH H H 
20 1b H 
 
 
2f CH3 H OH H H 
6 
 
21 1b H 
 
 
2g H H OCH3 CH3 H 
22 1b H 
 
 
2h CH3 H OCH3 CH3 H 
23 1b H 
 
 
2i H H OH CH3 H 
24 1b H 
 
 
2j H H F H H 
25 1b H 
 
 
2l H H H CBR 
26 1c CH3 OCH3 2a H H H H H 
27 1c CH3 OCH3 2b CH3 H H H H 
28 1c CH3 OCH3 2n 
 
 
H H H H 
29 1c CH3 OCH3 2c H H OCH3 H H 
30 1c CH3 OCH3 2g H H OCH3 CH3 H 
31 1c CH3 OCH3 2e H H OH H H 
32 1c CH3 OCH3 2i H H OH CH3 H 
33 1c CH3 OCH3 2o H OCH3 H H OCH3 
34 1c CH3 OCH3 2m H OCH3 OCH3 OCH3 H 
35 1c CH3 OCH3 2k H H Cl H H 
36 1c CH3 OCH3 2p H Cl H H Cl 
37 1c CH3 OCH3 2l H H H CBR 
38 1d H 
 
2a H H H H H 
39 1d H 
 
2c H H OCH3 H H 
40 1d H 
 
2k H H Cl H H 
41 1d H 
 
2q H H H Cl H 
42 1d H 
 
2l H H H CBR 
43 1e CH3 
 
2b CH3 H H H H 
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44 1e CH3 
 
2n 
 
H H H H 
45 1e CH3 
 
2c H H OCH3 H H 
46 1e CH3 
 
2g H H OCH3 CH3 H 
47 1e CH3 
 
2e H H OH H H 
48 1e CH3 
 
2j H H F H H 
49 1e CH3 
 
2k H H Cl H H 
50 1e CH3 
 
2r H F H H H 
51 1e CH3 
 
2s H Cl H H H 
52 1e CH3 
 
2q H H H Cl H 
      CBR = condensed benzene ring 
 
 
All the new derivatives were evaluated according to protocols available at the National Cancer 
Institute (NCI, Bethesda, MD). The most active ones were examined to determine the potential 
inhibition of tubulin assembly and their effects on the binding of [3H]colchicine to tubulin. In 
addition, the effects of selected compounds on the growth of human peripheral blood lymphocytes 
derived from healthy donors were assessed. The ability to induce apoptosis in cancer cells was also 
investigated. Finally, the most active compound was examined for its antitumor activity in vivo. 
 
2. Results and discussion 
2.1 Chemistry 
 Compounds 3-52 (Scheme 1 and Table 1) were prepared by means of a single step 
Knoevenagel reaction between aldehyde 1 and oxindole 2 in methanol/piperidine (33% NH4OH was 
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used instead of piperidine for compounds 39, 41 and 42 to improve the yield). Most derivatives were 
obtained as pure stereoisomers, but compounds 4, 12, 13, 15, 16, 21, 24, 25, 27, 36, 39-42, 44, 45 and 
49 were obtained as E/Z mixtures, with the ratio being determined on the basis of the 1H NMR spectra 
(see Experimental Section). In the case of compound 10, the two geometrical isomers were obtained 
and separated by fractional crystallization. In order to determine the geometrical configuration, one 
isomer was submitted to NOE experiments. The irradiation of the OCH3 (3.80 ppm) gave NOE at 
7.58 ppm, and this singlet was therefore assigned to ind-4. The second experiment enabled the 
assignment of the geometrical configuration, because irradiation of the singlet at 8.90 ppm (methine 
bridge) gave NOE at 7.58 ppm (ind-4), which agrees with the Z configuration. 
By comparing the 1H NMR spectra of the two isomers of compound 10, it emerged that the ind-4 
signal is located in a very different spectral zone. In particular, for the E isomer this signal is more 
shielded (6.04 ppm) than that of the Z isomer, which is much more deshielded (7.58 ppm). 
We observed that other 3-pyridyl and 4-pyridyl derivatives display this peculiar shift of the ind-4 
signal. Therefore, to study the geometrical configuration and this particular behavior, compounds 3, 
5, 6, 12, 14, 15, 17, 19 and 25 were submitted to NOE experiments. Specifically, we investigated the 
existence of a NOE connection between methine bridge and the ind-4 protons, in fact if a NOE 
connection is observed, the configuration is Z, otherwise it is E (Figure 1). Compounds 3, 5 and 14 
gave the results expected of E isomers, compounds 6, 17 and 19 of Z isomers, whereas for compounds 
12, 15 and 25, obtained as mixtures, the most abundant isomer has the Z configuration. 
The results obtained also confirmed that E isomers are characterized by a more shielded ind-4 signal, 
thus allowing the assignment of the stereochemical configuration of all the other 3-pyridyl and 4-
pyridyl derivatives (see Experimental Section). It is interesting to note that the synthesis of the 4-
pyridyl derivatives gave pure Z isomers or mixtures where the most abundant isomer has the Z 
configuration, whereas most of the 3-pyridyl derivatives has the E configuration. 
The stereochemical configurations of the derivatives bearing a methoxy group (26-37) or another 
imidazothiazole nucleus (38-52) at the 6 position of the imidazothiazole were also investigated. 
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Compounds 31 and 38 underwent NOE experiments. The results indicated that the configuration is E 
for both compounds, since no NOE correlation was observed between ind-4 and the methine bridge 
protons. The configurations of the other analogs were assigned by comparing the 1H NMR spectra. 
All the derivatives (or the most abundant isomer of the mixture) were E isomers (see Experimental 
Section). 
 
 
 
 
 
 
 
Fig. 1. E and Z isomers of 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones derivatives. 
 
The two isomers of compound 10 showed very similar antiproliferative profiles, thus confirming that 
no significant difference is attributable to the stereochemical configuration, as asserted in a previous 
study [5]. Therefore, compounds obtained as E/Z mixtures were used without resolving them in the 
NCI biological assays. 
The indolinones 2a, 2k and 2q are commercially available, the other oxindoles and aldehydes were 
prepared according to the literature [6-21], whereas, the synthesis of new aldehydes 1c, 1d and 1e is 
reported here. Aldehyde 1c was obtained from 6-chloro-2-methylimidazo[2,1-b]thiazole-5-
carbaldehyde (53) [22] by treatment with sodium methylate in CH3OH (Scheme 2). Aldehydes 1d 
and 1e were obtained by means of the Vilsmeier reaction on the corresponding imidazo[2,1-b]thiazole 
(57d,e), prepared in turn from 2-aminothiazole or 2-amino-5-methylthiazole, commercially available, 
and 2-bromo-1-(6-methylimidazo[2,1-b]thiazol-5-yl)ethan-1-one (55) [23] (Scheme 2). 
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Scheme 2. Synthesis of the new starting compounds. 
 
 
2.2. Biological analysis 
2.2.1. In vitro antiproliferative activities 
 Compounds 3-52 were initially tested at a single high concentration (10-5 M) in the full NCI 
60 cell panel (NCI 60 Cell One-Dose Screen). This panel is organized into subpanels representing 
leukemia, melanoma and cancers of the lung, colon, kidney, ovary, breast, prostate and central 
nervous system. Only compounds that satisfy predetermined threshold inhibition criteria in a 
minimum number of cell lines progress to the full 5-log concentration assay. The results are expressed 
as the percentage of growth of treated cells relative to the control following at 48 h incubation. The 
threshold inhibition criteria for progression were selected to efficiently capture compounds with 
antiproliferative activity based on analysis of historical Developmental Therapeutics Program (DTP) 
screening data. Fifteen out of fifty evaluated compounds were active in the preliminary test and 
progressed to the five-concentration assay, ranging from 10-9 to 10-4 M. Table 2 reports the results 
obtained at three assay endpoints: 50% growth inhibition (GI50), total cytostatic effect (TGI=Total 
Growth Inhibition) and cytotoxic effect (LC50), determined according to established NCI protocols 
(http://dtp.nci.nih.gov/branches/btb/ivclsp.html). For some compounds (15, 18, 29 and 37), the 5-
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concentration test was repeated, and no significant differences were found between the two assays. 
For these compounds, the data reported in Table 2 are the mean values of the two experiments.  
 
Table 2. Nine subpanels at five concentrations: growth inhibition, cytostatic and cytotoxic 
activity (M) of selected compounds. 
Compa Modes Leu-
kemia 
NSCLC Colon CNS Mela-
noma 
Ovarian Renal Prostate Breast MG-
MIDb 
 
14 
GI50 0.11 1.78 0.15 1.16 1.65 1.21 1.24 0.10 0.26 1.02 
TGI 46.42 16.22 9.42 13.90 17.62 12.28 15.88 11.09 20.11 17.81 
LC50 - 61.71 48.99 47.47 66.48 41.22 49.25 33.36 70.82 59.13 
 
15c 
GI50 2.65 8.97 0.68 1.60 3.27 2.34 14.94 1.10 5.42 5.37 
TGI 91.99 82.42 63.40 49.73 78.34 61.29 73.17 - 67.35 72.47 
LC50 - - 94.30 94.99 92.25 91.80 92.38 - - 95.67 
 
18c 
GI50 0.35 0.55 0.34 0.38 5.97 1.14 0.50 0.39 0.44 1.37 
TGI 81.79 82.43 78.75 63.07 85.27 62.42 65.45 68.75 80.14 74.63 
LC50 96.14 - 92.95 - - 93.21 - - - 97.92 
 
19 
GI50 10.08 21.17 7.50 4.46 15.81 33.83 42.97 14.98 4.43 18.64 
TGI 67.60 76.83 93.01 80.43 89.39 86.20 90.10 - 84.17 84.83 
LC50 - - - - 99.11 - - - - 99.86 
 
25 
GI50 0.03 11.12 0.03 0.04 7.16 0.05 11.77 0.02 0.04 4.51 
TGI 79.50 79.91 39.94 79.76 72.91 73.84 70.11 55.90 71.26 70.31 
LC50 - 97.87 77.05 94.30 95.26 79.95 - 80.13 99.03 92.50 
 
26 
GI50 0.50 5.68 0.80 1.97 16.19 6.29 3.53 2.09 2.52 5.17 
TGI 7.25 65.16 56.75 40.11 74.75 55.65 67.64 45.00 67.30 56.09 
LC50 93.67 99.03 93.26 87.87 94.90 96.31 - - - 95.98 
 
27 
GI50 4.35 9.50 4.05 9.82 8.08 10.51 13.12 12.60 4.82 8.69 
TGI 74.20 73.21 36.29 42.37 34.21 67.04 70.55 66.65 58.17 56.06 
12 
 
LC50 - 95.11 91.06 97.32 93.39 92.79 - - - 95.84 
 
29c 
GI50 0.43 1.49 0.32 0.43 3.46 1.32 0.65 0.38 0.87 1.18 
TGI - 58.65 35.73 33.56 67.65 42.63 61.82 52.78 61.32 57.12 
LC50 - 88.93 79.15 85.44 - 87.59 - - - 93.01 
 
30 
GI50 - 5.25 42.89 5.70 31.48 7.22 5.81 18.75 4.57 18.34 
TGI - 74.86 91.70 20.43 91.74 47.10 58.88 - 50.89 67.32 
LC50 - 98.04 - 68.28 - 91.39 90.64 - 91.40 92.95 
 
31 
GI50 3.32 7.54 4.79 4.76 4.88 12.85 6.58 7.59 4.57 6.53 
TGI 61.70 71.96 78.20 63.97 38.56 63.45 79.41 96.20 66.17 66.40 
LC50 - - 98.21 - 94.04 - - - - 98.82 
 
34 
GI50 5.73 9.26 6.89 7.79 7.86 13.82 9.36 11.35 5.37 8.70 
TGI - 58.80 69.89 33.58 65.65 63.24 45.03 - 29.23 56.95 
LC50 - 99.43 97.17 81.40 95.60 92.96 98.25 - 99.32 95.65 
 
37c 
GI50 0.34 2.82 0.37 0.42 0.52 0.62 1.06 0.30 0.79 0.94 
TGI 84.76 45.34 34.59 38.57 43.31 35.27 38.33 35.25 51.29 43.40 
LC50 - 91.41 71.07 82.92 94.97 91.25 89.60 75.93 - 89.19 
 
38 
GI50 35.33 6.72 3.48 3.74 4.81 7.60 7.44 3.48 2.73 6.95 
TGI - 65.57 17.70 26.91 62.27 61.35 70.29 33.95 22.21 52.43 
LC50 - 97.49 87.44 92.27 84.77 - 94.36 87.65 89.58 92.80 
 
41 
GI50 0.77 2.67 1.01 1.94 2.58 3.05 3.06 1.51 1.38 2.11 
TGI 7.28 18.11 12.50 11.69 16.72 21.49 20.30 9.30 13.37 15.37 
LC50 61.91 64.68 54.76 44.50 52.16 75.22 64.68 61.70 72.75 60.42 
 
42 
GI50 0.15 0.28 0.17 0.21 1.60 0.24 0.26 0.20 0.16 0.43 
TGI 1.72 8.17 2.82 5.15 7.02 10.16 8.29 4.24 5.88 6.23 
LC50 40.24 39.02 25.95 30.64 26.36 35.17 29.44 15.75 33.16 31.61 
a
 Highest conc. = 100 M, only modes showing a value <100 M are reported. The compound exposure time was 48 h. 
b
 Mean graph midpoint: average value for all cell lines tested; i.e., mean GI50. 
c
 Mean of two separate experiments. 
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The tested compounds showed a mean GI50 range between 0.43 and 18.64 M. Owing to their 
interesting antiproliferative profiles, compounds 14, 25, 26, 41, and 42 were submitted to the 
Biological Evaluation Committee (BEC) of the NCI for possible future development.  
Most of the compounds bearing a methyl group at position 2 and a methoxy group at position 6 of 
the imidazothiazole moiety entered the five-concentration assay. For these derivatives the best results 
were obtained by introducing a methoxy group at the 5 position of indolinone ring (compound 29, 
mean GI50 1.18 µM) and especially if the 6-methoxy-2-methylimidazo[2,1-b]thiazole is condensed 
with the 6,7-benzoindolinone, in fact compound 37 showed in most panels mean GI50 values in the 
submicromolar range. The exploration of indolinone N-methylation led to a reduction of the 
antiproliferative activity, in fact compound 27 showed a lower cytotoxicity compared to compound 
26 (mean GI50 8.69 µM vs. mean GI50 5.17 µM). 
The introduction of another imidazothiazole nucleus at the 6 position of the imidazothiazole nucleus 
did not lead to particular advantages, and resulted detrimental for the activity if the primary 
imidazothiazole bears also a methyl group at position 2 (compounds 43-52), in fact none of these 
derivatives reached the five-concentration assay. Better results were obtained if the biimidazothiazole 
is condensed with 6-chloro-2-indolinone (compound 41, mean GI50 2.11 µM) or, even better, with 
6,7-benzoindolinone, indeed compound 42 showed good antiproliferative activity, especially against 
leukemia (mean GI50=0.15 µM), colon (mean GI50=0.17 µM) and breast (mean GI50=0.16 µM) cancer 
cell lines. 
Comparing the series of 3-pyridyl (3-14) and 4-pyridyl (15-25) derivatives, better results were 
obtained with the 4-pyridyl derivatives, in fact a larger number of compounds progressed to the five-
concentration assay. Indeed, the only 3-pyridyl derivative active in the NCI 60 cell One-Dose Screen 
was compound 14 which resulted very active (mean GI50=1.02 µM) and derives from the 6,7-
benzoindolinone. Interestingly, compound 25, obtained by condensing the 6-(pyridin-4-
14 
 
yl)imidazo[2,1-b]thiazole-5-carbaldehyde with the 6,7-benzoindolinone showed mean GI50 values 
between 20 and 50 nM for leukemia, colon, CNS, ovarian, prostate and breast panels, thus resulting 
the most interesting derivative of the series.  
Overall these findings appointed the 6,7-benzoindolinone as a useful synthon, which allowed to 
obtain the most active derivatives either if the 6 position of the imidazothiazole system bears a 3-
pyridyl (14), a 4-pyridyl (25), a methoxy (37) group, or another imidazothiazole moiety (42). 
 
2.2.2. Effects of test compounds in non-tumor cells 
 To obtain a preliminary indication of the cytotoxic potential of these derivatives in normal 
human cells, compounds 14, 25 and 42 were evaluated in vitro against peripheral blood lymphocytes 
(PBL) from healthy donors (Table 3). The three compounds were weakly active in quiescent 
lymphocytes, having GI50 values in the range of 3-33 µM. With the mitogenic stimulus of 
phytohematoaglutinin (PHA), the GI50 values were little changed, except the GI50 of compound 42, 
which was reduced 2-fold, from 33.2 to 14.9 µM. The GI50 values obtained with the lymphocytes 
were 100-200 times higher than those observed against the leukemia cell lines. These data indicate 
that the tested derivatives are endowed with a modest effect both in quiescent and in rapidly 
proliferating normal lymphocytes.  
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Table 3. Cytotoxicity on human peripheral blood lymphocytes (PBL) 
 
 
 
 
 
 
a
 Compound 
concentration 
required to 
reduce cell 
growth inhibition 
by 50%. 
b
 PBL not 
stimulated with 
PHA 
c
 PBL stimulated with PHA. 
Values are the mean ± SEM for three separate experiments. 
 
 
2.2.3. Inhibition of tubulin polymerization and colchicine binding 
 On the basis of the NCI 60 Cell Screen data, the BEC proposed some derivatives as possible 
inhibitors of tubulin polymerization. Therefore, compounds 14, 25, 26, 41 and 42 were tested for 
potential inhibition of tubulin assembly (Table 4) in comparison with the potent colchicine site agent 
combretastatin A-4 (CA-4) [24]. Compounds 14, 26 and 42 inhibited tubulin assembly showing IC50 
values of 2.2-4.4 µM, with the IC50 defined as the concentration of compound that inhibits by 50% 
the extent of assembly of 10 µM tubulin after a 20 min incubation at 30 °C (the value for CA-4 was 
0.64 µM). Compound 25 was moderately active (IC50=14 µM), while compound 41 yielded an IC50 
> 20 µM, possibly due to poor solubility in the assay solution (0.8 M monosodium glutamate). 
 
Compound  
GI50 (µM)a 
PBLrestingb  PBLPHAc 
14 3.1±0.18 2.5±0.06 
25 4.5±0.20 5.5±0.32 
42 33.2±3.4 14.9±0.6 
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Thus, the order of inhibitory effects on tubulin polymerization was CA-4>14>26>42>>25>>41. This 
order of activity as inhibitors of tubulin assembly does not correlate well with their order of activity 
as antiproliferative agents.  
The compounds were also evaluated for their effects on the binding of [3H]colchicine to tubulin [25] 
at 5 M and 50 M concentrations (Table 4). As in the assembly assay, all the compounds were less 
potent than CA-4, which in these experiments inhibited colchicine binding by 98%, at the 
concentration of 5 M.  
 
Table 4. Inhibitory effects on tubulin assembly and colchicine binding to tubulin. 
Compound 
Tubulin assemblya 
IC50±SD (M) 
Colchicine bindingb 
% inhibition±SD 
5 M inhibitor        50 M inhibitor 
14 2.2 ± 0.2 31 ± 5 56 ± 4 
25 14 ± 2 25 ± 3 51 ± 2 
26 3.4 ± 0.2 39 ± 4 81 ± 0.9 
41  > 20 15 ± 9 28 ± 8 
42 4.4 ± 0.8 12 ± 3 28 ± 3 
CA-4 0.64 ± 0.01 98 ± 1 n.d. 
a
 Inhibition of tubulin polymerization. Tubulin was at 10 M. 
b
 Inhibition of [3H]colchicine binding. Tubulin and colchicine were at 1 and 5 M respectively, whereas the tested 
compounds were at 5 and 50 M. 
n.d.: not determined 
 
 
 
2.2.4. Compounds 14, 25, and 42 induce mitotic arrest of the cell cycle 
17 
 
 The effects of 24 h of treatment with different concentrations of compounds 14, 25 and 42 on 
cell cycle progression were determined by flow cytometry in HeLa, HT-29, and A549 cells (Figure 
2). Compounds 14 and 25 caused a significant G2/M arrest in a concentration-dependent manner, 
with a rise in G2/M cells occurring at a concentration as low as 50 nM, in particular for compound 
25, while at higher concentrations more than 80% of the cells were arrested in G2/M for both 
compounds. The cell cycle arrest in G2/M phase was accompanied by a rapid and significant 
reduction of the G1 and S phase cells. Compound 42 was less active in inducing G2/M arrest in the 
three cell lines tested. 
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Fig. 2. Percentage of cells in each phase of the cell cycle in HeLa, HT-29 and A549 cells treated 
with compounds 14, 25 and 42, at the indicated concentrations, for 24 h. Cells were fixed and 
labeled with PI and analyzed by flow cytometry as described in the Experimental Section. Data 
are shown as mean ± SEM of two independent experiments. 
 
 
To confirm that the accumulation of G2/M cells was due to mitotic arrest, we evaluated the mitotic 
index in K562 cells treated at different concentrations with compounds 14, 25 and 26 and with 
CA-4 as a positive control. The mitotic index is defined as the number of cells with condensed 
chromosomes, and indicated as a percentage of the total number of cells. With tubulin-active 
agents, these are considered cells in prometaphase, as generally there is little or no spindle 
formation. As shown in Table 5, compounds 14, 25, 26 and CA-4 all caused a marked increase in 
the mitotic index of K562 cells in comparison to the untreated cells which display a mitotic index 
of 3%. With all four compounds, this effect increased in a concentration dependent manner. 
 
Table 5. Mitotic studies with K562 leukemia cellsa 
Compound IC50 (nM) Mitotic Index (% of Mitotic cellsb) 
 
 IC50 5x IC50 10x IC50 
14 200 22 64 78 
25 30 12 35 58 
26 1000 42 61 80 
CA-4 4 15 32 61 
a Cells were grown in RPMI 1640 medium supplemented with 5% fetal bovine serum for 16 h (both for IC50 and 
mitotic index determinations) in a 5% CO2, humidified atmosphere at 37 °C.  
b Cells were smeared onto a glass slide, stained with Giemsa, and the proportion of cells with condensed chromosomes 
was determined. Without compounds the mitotic index was 3%. 
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We also studied the association between compound-induced G2/M arrest and alterations in G2/M 
regulatory protein expression in HeLa cells. As shown in Figure 3 (Panels A and B), compounds 
14 and 25 caused, in a time- and concentration-dependent manner, an increase in cyclin B1 
expression after a 24 h treatment. This was most evident for compound 25, which caused a 
significative expression of the protein even at 50 nM, the lowest concentration examined. This 
effect was confirmed by reduction in the expression of phosphatase cdc25c with both compounds. 
The phosphorylation of cdc25c directly stimulates its phosphatase activity, and this is necessary 
to activate cdc2/cyclin B on entry into mitosis [26,27]. In good agreement, we also observed a 
decrease of the phosphorylated form of cdc2 kinase. Again, compound 25 was the most potent of 
the two compounds examined. These findings together indicate that the tested compounds cause 
activation of the mitotic checkpoint following drug exposure. 
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Fig. 3. Effect of compounds 14 and 25 on cell cycle assembly checkpoint proteins. A) 
Representative immunoblot of HeLa cells treated for 24 h with the indicated concentrations of 
compounds. The cells were harvested and lysed for detection of the expression of the indicated 
protein by western blot analysis. To confirm equal protein loading, each membrane was stripped 
and reprobed with anti--actin antibody. B) Densitometric analysis of immunoblots.  Each band 
has been normalized to β-actin and represented as fold change respect to the untreated control. 
Differences between untreated controls and treated cells were analyzed using one-way ANOVA 
with Dunnett’s multiple comparison test. Data are expressed as mean ± SEM of three independent 
experiments. *p<0.05; **p<0.01; ***p<0.001 
 
 
2.2.5. Compounds 14, 25 and 42 induced apoptosis through the mitochondrial death pathway 
 To evaluate the cell death mode induced by the test compounds, we performed a 
biparametric cytofluorimetric analysis using propidium iodide (PI) and annexin-V-FITC, which 
stain DNA and externalized phosphatidylserine (PS) residues, respectively. We examined the 
ability of the compounds to induce apoptosis at different treatment times and concentrations, using 
two cell lines, HeLa and A549. In HeLa cells (Figure 4, panels A and B) all three compounds (14, 
25 and 42) induced apoptosis in a time- and concentration-dependent manner. In this cell line we 
used three different concentrations (250, 500 and 1000 nM), and, even at the lowest concentration, 
it is clear that compound 25 is the most active of the three compounds.  
We examined much lower compound concentrations with A549 cells (Figure 5, panels A and B) 
(12.5-100 nM). At these concentrations, minimal apoptosis occurred with compounds 14 and 42, 
even at 100 nM. Compound 25, however, showed high potency, inducing significant apoptosis 
even at 25 nM.  
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Fig. 4. A) Quantitative analysis of apoptotic cells after treatment of HeLa cells with the test 
compounds, at the indicated concentrations after incubation for 24 or 48 h. Data are represented as 
mean ± SEM of three independent experiments.  *p<0.05; **p<0.01; ***p<0.001 B) Representative flow 
cytometric plots of apoptotic cells, after 48 h of treatment with the indicated compounds at the 
concentration of 250 nM. The cells were harvested and labeled with annexin-V-FITC and PI and 
analyzed by flow cytometry. 
 
A 
B 
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Fig. 5. A) Quantitative analysis of apoptotic cells after treatment of A549 cells with the test 
compounds, at the indicated concentrations after incubation for 24 or 48 h. Data are represented as 
mean ± SEM of three independent experiments.  *p<0.05; **p<0.01; ***p<0.001 B) Representative flow 
cytometric plots of apoptotic cells, after 48 h of treatment with the indicated compounds at the 
concentration of 100 nM.  The cells were harvested and labeled with annexin-V-FITC and PI and 
analyzed by flow cytometry. 
 
Mitochondria play an essential role in the propagation of apoptosis [28,29]. At an early stage, 
apoptotic stimuli alter the mitochondrial transmembrane potential (mt). We therefore monitored 
mt by the fluorescence of the dye JC-1 [30]. HeLa cells treated with compound 14 or 25 (250-
500 nM) showed a time-dependent increase in the percentage of cells with low mt (Figure 6). 
The depolarization of the mitochondrial membrane
 
is associated with the appearance of annexin-
V positivity observed in the experiments described above. In fact, the decrease of mt is 
characteristic of apoptosis and has been observed with both microtubule stabilizing and 
destabilizing agents with a variety of cell types [29,31-33]. Compound 25 resulted the most potent 
of the two compounds. 
A 
B 
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Mitochondrial membrane depolarization is associated with mitochondrial production of reactive 
oxygen species (ROS) [34]. Therefore, we investigated whether ROS production increased after 
treatment with compounds 14 and 25. We utilized the fluorescence indicator 2,7-
dichlorodihydrofluorescein diacetate (H2-DCFDA). As shown in Figure 6, both compounds at 250 
nM induced significant production of ROS, starting after 12-24 h treatment, in good agreement 
with the mitochondrial depolarization study described above. 
 
Fig. 6. Assessment of mitochondrial membrane potential (mt) (upper panels) and production of 
ROS (lower panels) after treatment of HeLa cells with compounds 14 or 25. Cells were treated with 
the indicated concentration of compound for 6, 12, 24 or 48 h and then stained with the fluorescent 
probe JC-1 for analysis of mitochondrial potential or H2-DCFDA for the evaluation of ROS levels. 
Cells were then analyzed by flow cytometry as described in the Experimental Section. Data are 
represented as mean ± SEM of three independent experiments. *p<0.05; **p<0.01 vs control 
 
 25 
 
25 
 
2.2.6. Compounds 14 and 25 induce caspase-9, caspase -3, PARP activation and down-regulation 
of the anti-apoptotic proteins Bcl-2 and Mcl-1.  
 To further investigate the apoptotic machinery involved upon treatment of HeLa cells with 
compounds 14 and 25, we performed an immunoblot analysis to evaluate the activation of caspase-
9 and caspase-3 which are the main caspases involved in mitochondrial apoptosis. As depicted in 
figure 7 (panels A and B), both caspases are activated after incubation of HeLa cells for 24 h with 
either compounds. Moreover, the cleavage of poly(ADP-ribose) polymerase (PARP), which is one 
of the main cleavage targets of caspase-3, occurred with compound 25 even at the lowest 
concentration used (50 nM), in good agreement with all the other biological assays (Figure 7). We 
also investigated the expression of two anti-apoptotic proteins, Mcl-1 and Bcl-2 (Figure 7). We 
and other research groups have shown that sensitivity to antimitotic drugs is regulated by Mcl-1 
levels [33,35], a member of the Bcl-2 family of anti-apoptotic proteins. This protein is frequently 
overexpressed in many cancers and is capable of antagonizing pro-apoptotic proteins and 
preventing the loss of mitochondrial membrane potential [36]. Bcl-2 is another anti-apoptotic 
protein that facilitates tumorigenesis and tumor progression [36]. We found that the expression of 
both Mcl-1 and Bcl-2 was reduced after a 24 h treatment with either compound, while the Mcl-1 
was particularly down regulated by treatment with compound 25. 
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Fig. 7.  A) Western blot analysis of Bcl-2, Mcl-1, cleaved Caspase-9, cleaved Caspase-3 and 
PARP, after treatment of HeLa cells with compounds 14 or 25 at the indicated concentrations for 
24 h. To confirm equal protein loading, each membrane was stripped and reprobed with anti--
actin antibody. B) Densitometric analysis of immunoblots.  Each band has been normalized to β-
actin and represented as fold change respect to the untreated control. Differences between 
untreated controls and treated cells were analyzed using one-way ANOVA with Dunnett’s multiple 
comparison test. Data are expressed as mean ± SEM of three independent experiments. *p<0.05; 
**p<0.01; ***p<0.001 
 
2.2.7. Evaluation of antitumor activity of compound 25 in vivo. 
A 
B 
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 To determine the in vivo antitumor activity of 25, two different syngeneic murine models 
were used [37], represented by the BL6-B16 mouse melanoma cell line and the murine breast 
cancer cell line EO771. Preliminary in vitro experiments were carried out to evaluate the 
cytotoxicity of compound 25 in both murine tumor cell lines. The GI50 obtained after 72 h was 305 
± 45 nM and 15 ± 4.5 nM in BL6-B16 and EO771 cells, respectively.  
Both BL6-B16 and E0771 cell lines were injected subcutaneously in syngeneic C57BL/6 mice. 
Once the tumor reached a measurable size (about 100 mm3), mice were randomly assigned to 
different experimental groups and treated intraperitoneally every other day with vehicle (DMSO), 
compound 25 (at doses of 7.5 or 15 mg/kg) or with Combretastatin 4-A phosphate (CA-4P) (at 30 
mg/kg) as a reference compound. 
As shown in Figure 8 (Panel A), compound 25 caused a significant reduction of BL6-B16 
melanoma cells growth (29.4%) at the dose of 15 mg/kg, if compared with vehicle-treated group. 
The reductions observed with 7.5 mg/kg (18%) and CA-4P (16-18%) did not reach statistical 
significance. Notably, in the E0771 breast cancer model (Figure 8, Panel B), treatment with 
compound 25 induced a significant reduction of tumor volume at both the doses of 15 mg/kg 
(56.8% of reduction) and 7.5 mg/kg (51.8% of reduction). Indeed, treatment with the reference 
compound CA-4P at 30 mg/kg caused only a small reduction in tumor volume (30.9%) if compared 
with both doses of compound 25. Under the safety/tolerability point of view, no significant 
variation in body weight occurred in animals treated with 25 at the higher concentration (data not 
shown).  
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Fig. 8. Inhibition of mouse allograft growth in vivo by compound 25. Male C57BL/6 mice were 
injected subcutaneously at their dorsal region with 107 BL6-B16 murine melanoma cells (Panel 
A) or EO771 cells (Panel B). Tumor-bearing mice were administered the vehicle, as control, or 15 and 
7.5 mg/kg of 25 or CA-4P as reference compound at the dose of 30 mg/kg. Injections were given 
intraperitoneally at the days indicated by the arrows. Arrows indicate times of administration. Data are 
presented as mean ± SEM of tumor volume at each time point for 5 animals per group. ***p<0.01, *p<0.05 
vs. control. 
 
 
A 
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3. Conclusions 
 The synthesis of a library composed of fifty new 3-(5-imidazo[2,1-b]thiazolylmethylene)-
2-indolinones allowed the identification of some derivatives characterized by an interesting 
antiproliferative profile and GI50 values in the nanomolar range. Remarkable, when tested in 
human peripheral blood lymphocytes from healthy donors, compounds 14, 25 and 42 resulted 100-
200 times less cytotoxic than against leukemia cell lines, showing a modest effect in both quiescent 
and rapidly proliferating normal lymphocytes. The investigation of the mechanism of action 
included several studies. First, some derivatives were selected by BEC to determine their effects 
on tubulin assembly and [3H]colchicine binding, but the inhibition of tubulin polymerization does 
not correlate perfectly with the antiproliferative activity, and the tested compounds resulted less 
active than CA-4 in inhibiting colchicine binding. Flow cytometric analysis performed on HeLa, 
HT-29, and A549 cells, showed that compounds 14 and 25 caused a cell cycle arrest in G2/M 
phase, attributable to a mitotic arrest, as indicated by the increase of the mitotic index. In addition, 
compounds 14 and 25 caused in HeLa cells an increase in cyclin B1 expression, more evident for 
compound 25. This effect was confirmed by reduction of phosphatase cdc25c expression, and in 
good agreement, a decrease of the phosphorylated form of cdc2 kinase. These findings are 
compatible with the activation of the mitotic checkpoint, thus suggesting that these derivatives 
may interfere with microtubules dynamic. Interestingly, the study of cell death mode proved that 
compounds 14 and 25 induced apoptosis (25 even at 25 nM) through the mitochondrial death 
pathway, causing a strong reduction of the mitochondrial anti-apoptotic proteins Bcl-2 and Mcl-1 
expression and in parallel the significant activation of both caspase-9 and -3 and consequent PARP 
cleavage. Finally, when tested in vivo for its antitumor potential, compound 25 caused a significant 
reduction of tumor growth on both melanoma (BL6-B16) and breast cancer (E0771) cells, with a 
therapeutic effect greater than that of CA-4P, the reference compound. 
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In conclusion, compound 25 emerges as a new effective anticancer drug candidate and as a new 
lead compound, which may inspire the synthesis of new analogues endowed with even better 
biological profiles. 
 
 
4. Experimental section 
4.1. Chemical synthesis  
 The melting points are uncorrected. TLC was performed on Fluka plates (art. 99577) and 
column chromatography on Silica gel 70-200  60A (Fluorochem): the eluent was a mixture of 
petroleum ether/acetone in various proportions. Analyses indicated by the symbols of the elements 
were within ± 0.4% of the theoretical values. The IR spectra were recorded in nujol on a Nicolet 
Avatar 320 E.S.P.; max is expressed in cm-1. The 1H NMR and 13C NMR spectra were recorded 
on a Varian MR 400 MHz (ATB PFG probe); the chemical shift (referenced to solvent signal) is 
expressed in  (ppm) and J in Hz (abbreviations: ar=aromatic, ind=indole, py=pyridine, 
th=thiazole). Compounds 4, 12, 13, 15, 16, 21, 24, 25, 27, 36, 39-42, 44, 45 and 49 were obtained 
as E/Z mixtures, the ratio was determined on the basis of the 1H NMR spectra. The ppm reported 
in 1H NMR spectra are related to the most prevalent isomer. Only 13C NMR spectra of 
representative compounds obtained as pure isomers were described. 
All solvents and reagents were supplied by Aldrich Chemical Co. Ltd. and were used as supplied. 
The 2-aminothiazole (54d), 2-amino-5-methylthiazole (54e), the oxindoles 2a, 2k and 2q are 
commercially available. The following compounds were prepared according to the literature: 53 
[22], 55 [23], 1a-b [21], 2b [6], 2c [7], 2d [8], 2e [9], 2f [8], 2g [10], 2h [11], 2i [12], 2j [13], 2l 
[14], 2m [15], 2n [16], 2o [17], 2p [18], 2r [19], and 2s [20]. 
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4.1.1. General procedure for the synthesis of compounds 3-52. 
The appropriate compound 2 (10 mmol) was dissolved in methanol (100 mL) and treated with the 
equivalent of the appropriate aldehyde 1 and piperidine (1 mL). For compounds 39, 41 and 42 the 
yield was much lower (5%), and an improvement (15-20%) was obtained by replacing piperidine 
with 33% NH4OH  
The reaction mixture was refluxed for 5-10 h, except for compounds 39-42 which required a longer 
reflux time (16-24 h; the progress of the reaction was followed by TLC). The precipitate, formed 
on cooling, was collected by filtration. 
Compounds 39-41 were purified by column chromatography with petroleum ether/acetone as the 
eluent. Most of the crude products were crystallized from methanol, except 27 (acetone/petroleum 
ether), 34, 43-48, 50-52 (ethanol) and 42, 49 (toluene). In the case of compound 10, the two E/Z 
isomers were isolated by fractional crystallization from methanol . 
 
(E)-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (3). Yellow solid; 
58% yield; mp 298-300 °C. IR cm-1 1700, 1607, 1151, 722. 1H NMR (DMSO-d6, 400 MHz) 6.43 
(1H, d, ind J=7.6 Hz), 6.71 (1H, t, ind, J=7.6 Hz), 6.87 (1H, d, ind, J=7.6 Hz), 7.17 (1H, t, ind, 
J=7.6 Hz), 7.44 (1H, d, th, J=4.6 Hz), 7.58 (1H, d, th, J=4.6 Hz), 7.66 (1H, s, CH), 8.07 (2H, m, 
py), 8.48 (1H, m, py), 8.86 (1H, s, py), 10.69 (1H, s, NH). Elemental analysis calcd (%) for 
C19H12N4OS (MW 344.39) C 66.26, H 3.51, N 16.27. Found C 66.02, H 3.47, N 16.38. 
 
1-Methyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (4). Yellow 
solid; 47% yield; E/Z 19/81; mp 245-247 °C. IR cm-1 1685, 1608, 1258, 743. 1H NMR (DMSO-
d6, 400 MHz) 3.20 (3H, s, N-CH3), 7.07 (2H, m, ind), 7.35 (2H, m, th+ind), 7.52 (1H, dd, py-5, 
J=8.0, 4.8 Hz), 7.65 (1H, d, th, J=4.4 Hz), 7.83 (1H, d, ind, J=8.4 Hz), 7.87 (1H, s, CH), 8.09 (1H, 
d, py-6, J=8.0 Hz), 8.58 (1H, s, py-4, J=4.8 Hz), 8.89 (1H, d, py-2, J=2.0 Hz). Elemental analysis 
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calcd (%) for C20H14N4OS (MW 358.42) C 67.02, H 3.94, N 15.63. Found C 67.30, H 4.01, N 
15.44. 
 
(E)-5-methoxy-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (5). 
Orange solid; 30% yield; mp 305-310 °C. IR cm-1 1711, 1260, 1004, 881. 1H NMR (DMSO-d6, 
400 MHz) 3.41 (3H, s, O-CH3), 6.00 (1H, s, ind-4), 6.77 (2H, s, ind), 7.42 (1H, dd, py-5, J=7.6, 
4.0 Hz), 7.48 (1H, d, th, J=4.2 Hz), 7.66 (1H, d, th, J=4.2 Hz), 7.69 (1H, s, CH), 8.08 (1H, d, py-
6, J=7.6 Hz), 8.51 (1H, d, py-4, J=4.0 Hz), 8.91 (1H, d, py-2, J=2.0 Hz), 10.50 (1H, s, NH). 
Elemental analysis calcd (%) for C20H14N4O2S (MW 374.42) C 64.16, H 3.77, N 14.96. Found C 
63.98, H 3.88, N 15.01. 
 
(Z)-5-methoxy-1-methyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(6). Red solid; 40% yield; mp 270-280 °C. IR cm-1 1876, 1623, 1125, 820. 1H NMR (DMSO-d6, 
400 MHz) 3.16 (3H, s, N-CH3), 3.76 (3H, s, O-CH3), 6.92 (1H, dd, ind-6, J=8.4, 1.8 Hz), 6.96 
(1H, d, ind-7, J=8.4 Hz), 7.35 (1H, d, th, J=4.8 Hz), 7.52 (1H, dd, py-5, J=8.0, 4.4 Hz), 7.57 (1H, 
d, ind-4, J=1.8 Hz), 7.62 (1H, d, th, J=4.8 Hz), 7.92 (1H, s, CH), 8.09 (1H, d, py-6, J=8.0 Hz), 
8.58 (1H, d, py-4, J=4.8 Hz), 8.89 (1H, d, py-2, J=2.4 Hz). Elemental analysis calcd (%) for 
C21H16N4O2S (MW 388.45) C 64.93, H 4.15, N 14.42. Found C 65.00, H 4.28, N 14.22. 
 
(E)-5-hydroxy-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (7). Red 
solid; 73% yield; mp >310 °C. IR cm-1 1704, 1263, 1199, 812. 1H NMR (DMSO-d6, 400 MHz) 
5.96 (1H, d, ind-4, J=2.0 Hz), 6.59 (1H, dd, ind-6, J=8.0, 2.0 Hz), 6.67 (1H, d, ind-7, J=8.0 Hz), 
7.46 (2H, m, th+py-5), 7.55 (1H, d, th, J=4.4 Hz), 7.59 (1H, s, CH), 8.08 (1H, d, py-6, J=8.0 Hz), 
8.51 (1H, d, py-4, J=4.8 Hz), 8.85 (1H, s, OH), 8.90 (1H, d, py-2, J=2.4 Hz), 10.37 (1H, s, NH). 
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Elemental analysis calcd (%) for C19H12N4O2S (MW 360.39) C 63.32, H 3.36, N 15.55. Found C 
63.54, H 3.47, N 15.25. 
 
(E)-5-hydroxy-1-methyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(8). Red solid; 59% yield; mp 296-298 °C. IR cm-1 1690, 1639, 1234, 902. 1H NMR (DMSO-d6, 
400 MHz) 3.18 (3H, s, N-CH3), 6.01 (1H, d, ind-4, J=2.0 Hz), 6.67 (1H, dd, ind-6, J=8.4, 2.0 
Hz), 6.84 (1H, d, ind-7, J=8.4 Hz), 7.46 (1H, dd, py-5, J=8.0, 4.8 Hz), 7.47 (1H, d, th, J=4.8 Hz), 
7.57 (1H, d, th, J=4.8 Hz), 7.68 (1H, s, CH), 8.32 (1H, d, py-6, J=8.0 Hz), 8.51 (1H, d, py-4, J=4.8 
Hz), 8.90 (1H, d, py-2, J=2.4 Hz), 8.96 (1H, s, OH). Elemental analysis calcd (%) for C20H14N4O2S 
(MW 374.42) C 64.16, H 3.77, N 14.96. Found C 64.02, H 3.59, N 15.02. 
 
(E)-5-methoxy-6-methyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(9). Red solid; 63% yield; mp 249-251 °C. IR cm-1 1704, 1614, 1263, 1193. 1H NMR (DMSO-d6, 
400 MHz) 2.10 (3H, s, CH3), 3.30 (3H, s, O-CH3), 5.99 (1H, s, ind), 6.67 (1H, s, ind), 7.44 (1H, 
dd, py-5, J=8.4, 4.8 Hz), 7.47 (1H, d, th, J=4.4 Hz), 7.63 (1H, s, CH), 7.66 (1H, d, th, J=4.4 Hz), 
8.09 (1H, d, py-6, J=8.4 Hz), 8.51 (1H, d, py-4, J=4.8 Hz), 8.93 (1H, d, py-2, J=2.4 Hz), 10.44 
(1H, s, NH). Elemental analysis calcd (%) for C21H16N4O2S (MW 388.45) C 64.93, H 4.15, N, 
14.42. Found C 65.01, H 4.02, N 14.64. 
 
(Z)-5-methoxy-1,6-dimethyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-
one (10). Black solid; 35% yield; mp 264-266 °C. IR cm-1 1690, 1263, 1096, 688. 1H NMR 
(DMSO-d6, 400 MHz) 2.24 (3H, s, CH3), 3.15 (3H, s, N-CH3), 3.79 (3H, s, O-CH3), 6.89 (1H, 
s, ind), 7.34 (1H, d, th, J=4.8 Hz), 7.53 (1H, dd, py-5, J=8.0, 4.8 Hz), 7.57 (1H, s, ind), 7.58 (1H, 
d, th, J=4.8 Hz), 7.88 (1H, s, CH), 8.10 (1H, d, py-6, J=8.0 Hz), 8.58 (1H, d, py-4, J=4.8 Hz), 8.89 
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(1H, d, py-2, J=2.0 Hz). Elemental analysis calcd (%) for C22H18N4O2S (MW 402.47) C 65.65, H 
4.51, N 13.92. Found C 65.78, H 4.62, 13.99. 
 
(E)-5-methoxy-1,6-dimethyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-
one (10). Dark red solid; 35% yield; mp 244-246 °C. IR cm-1 1702, 1234, 1165, 863. 1H NMR 
(DMSO-d6, 400 MHz) 2.15 (3H, s, CH3), 3.20 (3H, s, N-CH3), 3.32 (3H, s, O-CH3), 6.04 (1H, 
s, ind), 6.90 (1H, s, ind), 7.45 (1H, dd, py-5, J=8.4, 4.8 Hz), 7.48 (1H, d, th, J=4.8 Hz), 7.67 (1H, 
d, th, J=4.8 Hz), 7.72 (1H, s, CH), 8.09 (1H, d, py-6, J=8.4 Hz), 8.51 (1H, d, py-4, J=4.8 Hz), 8.93 
(1H, d, py-2, J=2.0 Hz). Elemental analysis calcd (%) for C22H18N4O2S (MW 402.47) C 65.65, H 
4.51, N 13.92. Found C 65.53, H 4.60, N 13.98. 
 
(E)-5-hydroxy-6-methyl-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(11). Red solid; 68% yield; mp >320 °C. IR cm-1 1710, 1633, 1266, 1186.  1H NMR (DMSO-d6, 
400 MHz) 2.07 (3H, s, CH3), 6.03 (1H, s, ind), 6.58 (1H, s, ind), 7.47 (4H, m, 2th+py-5+CH), 
8.09 (1H, d, py-6, J=8.0 Hz), 8.51 (1H, d, py-4, J=4.0 Hz), 8.72 (1H, s, OH), 8.92 (1H, d, py-2, 
J=2.0 Hz), 10.31 (1H, s, NH). Elemental analysis calcd (%) for C20H14N4O2S (MW 374.42) C 
64.16, H 3.77, N 14.96. Found C 64.56, H 3.84, N 15.01. 
 
5-Fluoro-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (12). Orange 
solid; 90% yield; E/Z 16/84; mp >310 °C. IR cm-1 1697, 1266, 1156, 803. 1H NMR (DMSO-d6, 
400 MHz) 6.85 (1H, m, ind), 7.06 (1H, m, ind), 7.37 (1H, d, th, J=4.4 Hz), 7.53 (1H, dd, py-5, 
J=7.8, 4.4 Hz), 7.65 (1H, d, th, J=4.4 Hz), 7.75 (1H, m, ind), 7.92 (1H, s, CH), 8.10 (1H, d, py-6, 
J=7.8 Hz), 8.60 (1H, d, py-4, J=4.4 Hz), 8.90 (1H, d, py-2, J=2.4 Hz), 10.59 (1H, s, NH). Elemental 
analysis calcd (%) for C19H11FN4OS (MW 362.38) C 62.97, H 3.06, N 15.46. Found C 63.03, H 
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5-Chloro-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (13). Orange 
solid; 85% yield; E/Z 23/77; mp 294-296 °C. IR cm-1 1698, 1264, 1201, 804. 1H NMR (DMSO-
d6, 400 MHz) 6.87 (1H, d, ind-7, J=7.8 Hz), 7.27 (1H, dd, ind-6, J=7.8, 1.6 Hz), 7.38 (1H, d, 
th, J=4.5 Hz), 7.53 (2H, m, py), 7.66 (1H, d, th, J=4.5 Hz), 7.78 (1H, s, py), 7.96 (1H, d, ind-4, 
J=1.6 Hz), 7.98 (1H, s, CH), 8.10 (1H, m, py), 10.70 (1H, s, NH). Elemental analysis calcd (%) 
for C19H11ClN4OS (MW 378.83) C 60.24, H 2.93, N 14.79. Found C 60.56, H 2.89, N 14.83. 
 
(E)-3-((6-(pyridin-3-yl)imidazo[2,1-b]thiazol-5-yl)methylene)-1,3-dihydro-2H-benzo[g]indol-2-
one (14). Red solid; 77% yield; mp >310 °C. IR cm-1 1701, 1609, 1254, 1024. 1H NMR (DMSO-
d6, 400 MHz) 6.67 (1H, d, ind, J=8.8 Hz), 7.26 (1H, d, ind, J=8.8 Hz), 7.42 (1H, dd, py-5, J=8.0, 
4.8 Hz), 7.44 (1H, d, th, J=4.4 Hz), 7.52 (2H, m, ind), 7.69 (1H, d, th, J=4.4 Hz), 7.73 (1H, s, CH), 
7.81 (1H, m, ind), 8.13 (2H, m, py-6+ind), 8.47 (1H, d, py-4, J=4.8 Hz), 8.94 (1H, d, py-2, J=2.4 
Hz), 11.46 (1H, s, NH). 13C NMR (DMSO-d6, 100 MHz)  114.9, 115.0, 118.6. 118.8, 119.0, 
120.5, 120.6, 120.7, 122.6, 123.8, 126.0, 127.2, 128.3, 128.4, 130.0, 133.7, 134.1, 140.3, 144.6, 
147.7, 148.7, 151.9, 169.4. Elemental analysis calcd (%) for C23H14N4OS (MW 394.45) C 70.03, 
H 3.58, N 14.20. Found C 70.24, H 3.62, N 14.34. 
 
3-((6-(Pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (15). Orange solid; 76% 
yield; E/Z 35/65; mp 310-313 °C. IR cm-1 1707, 1602, 1214, 722. 1H NMR (DMSO-d6, 400 MHz) 
6.88 (1H, d, ind-7, J=7.4 Hz), 7.01 (1H, t, ind, J=7.4 Hz), 7.27 (1H, t, ind, J=7.4 Hz), 7.37 (1H, 
d, th, J=4.5 Hz), 7.65 (1H, d, th, J=4.5 Hz), 7.70 (2H, m, py), 7.81 (1H, d, ind-4, J=7.4 Hz), 7.88 
(1H, s, CH), 8.64 (2H, m, py), 10.61 (1H, s, NH). Elemental analysis calcd (%) for C19H12N4OS 
(MW 344.39) C 66.26, H 3.51, N 16.27. Found C 66.15, H 3.59, N 16.38. 
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1-Methyl-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (16). Orange 
solid; 70% yield; E/Z 31/69; mp 306-307 °C. IR cm-1 1710, 1660, 1598, 722. 1H NMR (DMSO-
d6, 400 MHz) 3.19 (3H, s, N-CH3), 7.07 (1H, d, ind, J=7.6 Hz), 7.09 (1H, t, ind, J=7.6 Hz), 7.36 
(1H, t, ind, J=7.6 Hz), 7.37 (1H, d, th, J=4.4 Hz), 7.67 (1H, d, th, J=4.4 Hz), 7.68 (1H, d, ind, 
J=7.6 Hz), 7.70 (2H, m, py), 9.94 (1H, s, CH), 8.64 (2H, m, py). Elemental analysis calcd (%) for 
C20H14N4OS (MW 358.42) C 67.02, H 3.94, N 15.63. Found C 67.30, H 4.00, N 15.68. 
 
(Z)-5-methoxy-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (17). Dark 
red solid; 37% yield; mp 290-293 °C. IR cm-1 1701, 1603, 1194, 1025. 1H NMR (DMSO-d6, 400 
MHz) 3.76 (3H, s, O-CH3), 6.77 (1H, d, ind-7, J=8.4 Hz), 6.85 (1H, dd, ind-6, J=8.4, 2.0 Hz), 
7.36 (1H, d, th, J=4.4 Hz), 7.53 (1H, d, ind-4, J=2.0 Hz), 7.62 (1H, d, th, J=4.4 Hz), 7.70 (2H, d, 
py, J=5.6 Hz), 7.92 (1H, s, CH), 8.65 (2H, d, py, J=5.6 Hz), 10.40 (1H, s, NH). Elemental analysis 
calcd (%) for C20H14N4O2S (MW 374.42) C 64.16, H 3.77, N 14.96. Found C 64.34, H 3.81, N 
14.86. 
 
(Z)-5-methoxy-1-methyl-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(18). Red orange solid; 70% yield; mp 294-295 °C. IR cm-1 1686, 1600, 1229, 812. 1H NMR 
(DMSO-d6, 400 MHz) 3.15 (3H, s, N-CH3), 3.78 (3H, s, O-CH3), 6.95 (2H, m, ind), 7.37 (1H, 
d, th, J=4.6 Hz), 7.60 (1H, d, ind-4, J=2.0 Hz), 7.64 (1H, d, th, J=4.6 Hz), 7.69 (2H, d, py, J=5.6 
Hz), 7.98 (1H, s, CH), 8.65 (2H, d, py, J=5.6 Hz). 13C NMR (DMSO-d6, 100 MHz)  25.9, 55.7, 
107.4, 108.9, 109.5, 112.9, 114.9, 119.4, 120.2, 121.8, 122.7, 123.8, 127.0, 136.7, 140.8, 145.2, 
150.0, 155.2, 164.7. Elemental analysis calcd (%) for C21H16N4O2S (MW 388.45) C 64.93, H 4.15, 
N 14.42. Found C 64.88, H 4.09, N 14.55. 
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(Z)-5-hydroxy-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (19). Dark 
red solid; 64% yield; mp >320 °C. IR cm-1 1660, 1608, 1194, 763. 1H NMR (DMSO-d6, 400 MHz) 
6.69 (2H, m, ind), 7.19 (1H, d, ind-4, J=2.0 Hz), 7.35 (1H, d, th, J=4.8 Hz), 7.62 (1H, d, th, 
J=4.8 Hz), 7.69 (2H, dd, py, J=5.8, 1.4 Hz), 7.75 (1H, s, CH), 8.64 (2H, dd, py, J=5.8, 1.4 Hz), 
9.06 (1H, s, OH), 10.30 (1H, s, NH). 13C NMR (DMSO-d6, 100 MHz)  108.4, 110.0, 112.9, 
116.3, 118.4, 120.3, 121.7, 122.5, 124.6, 128.3, 134.2, 141.0, 144.9, 150.0, 151.2, 152.3, 166.5. 
Elemental analysis calcd (%) for C19H12N4O2S (MW 360.39) C 63.32, H 3.36, N 15.55. Found C 
63.44, H 3.44, N 15.48. 
 
(Z)-5-hydroxy-1-methyl-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(20). Dark red solid; 67% yield; mp >320 °C. IR cm-1 3389, 1672, 1605, 1003. 1H NMR (DMSO-
d6, 400 MHz) 3.12 (3H, s, N-CH3), 6.81 (1H, dd, ind-6, J=8.4, 2.2 Hz), 6.85 (1H, d, ind-7, J=8.4 
Hz), 7.27 (1H, d, ind-4, J=2.2 Hz), 7.36 (1H, d, th, J=4.4 Hz), 7.63 (1H, d, th, J=4.4 Hz), 7.69 (2H, 
dd, py, J=6.0, 1.4 Hz), 7.81 (1H, s, CH), 8.64 (2H, dd, py, J=6.0, 1.4 Hz), 9.16 (1H, s OH). 
Elemental analysis calcd (%) for C20H14N4O2S (MW 374.42) C 64.16, H 3.77, N 14.96. Found C 
64.38, H 3.86, N 14.83. 
 
5-Methoxy-6-methyl-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(21). Brown solid; 50% yield; E/Z 15/85; mp 282-284 °C. IR cm-1 1690, 1597, 1122, 722. 1H NMR 
(DMSO-d6, 400 MHz) 2.19 (3H, s, CH3), 3.79 (3H, s, O-CH3), 6.68 (1H, s, ind), 7.35 (1H, d, 
th, J=4.4 Hz), 7.53 (1H, s, ind), 7.59 (1H, d, th, J=4.4 Hz), 7.70 (2H, dd, py, J=5.6, 1.6 Hz), 7.87 
(1H, s, CH), 8.64 (2H, dd, py, J=5.6, 1.6 Hz), 10.35 (1H, s, NH). Elemental analysis calcd (%) for 
C21H16N4O2S (MW 388.45) C 64.93, H 4.15, N 14.42. Found C 64.89, H 4.00, N 14.63. 
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(Z)-5-methoxy-1,6-dimethyl-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-
one (22). Red orange solid; 39% yield; mp 304-306 °C. IR cm-1 1684, 1599, 1264, 1165. 1H NMR 
(DMSO-d6, 400 MHz) 2.24 (3H, s, CH3), 3.14 (3H, s, N-CH3), 3.81 (3H, s, O-CH3), 6.90 (1H, 
s, ind), 7.35 (1H, d, th, J=4.8 Hz), 7.60 (2H, m, th+ind), 7.70 (2H, dd, py, J=6.0, 1.8 Hz), 7.94 
(1H, s, CH), 8.64 (2H, dd, py, J=6.0, 1.8 Hz). Elemental analysis calcd (%) for C22H18N4O2S (MW 
402.47) C 65.65, H 4.51, N 13.92. Found C 65.74, H 4.19, N 13.67. 
 
(Z)-5-hydroxy-6-methyl-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(23). Dark red solid; 53% yield; mp >320 °C. IR cm-1 3192, 1690, 1603, 1191. 1H NMR (DMSO-
d6, 400 MHz) 2.16 (3H, s, CH3), 6.61 (1H, s, ind), 7.11 (1H, s, ind), 7.34 (1H, d, th, J=4.2 Hz), 
7.57 (1H, s, CH), 7.59 (1H, d, th, J=4.2 Hz), 7.68 (2H, dd, py, J=6.0, 1.6 Hz), 8.63 (2H, dd, py, 
J=6.0, 1.6 Hz), 8.93 (1H, s, OH), 10.25 (1H, s, NH). Elemental analysis calcd (%) for C20H14N4O2S 
(MW 374.42) C 64.16, H 3.77, N 14.96. Found C 64.25, H 3.78, N 15.00. 
 
5-Fluoro-3-((6-(pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (24). Orange 
solid; 67% yield; E/Z 24/76; mp >320 °C. IR cm-1 1693, 1604, 1193, 778. 1H NMR (DMSO-d6, 
400 MHz) 6.85 (1H, m, ind), 7.07 (1H, m, ind), 7.38 (1H, d, th, J=4.5 Hz), 7.66 (1H, d, th, J=4.5 
Hz), 7.70 (2H, m, py), 7.78 (1H, m, ind), 7.98 (1H, s, CH), 9.66 (2H, m, py), 10.61 (1H, s, NH). 
Elemental analysis calcd (%) for C19H11FN4OS (MW 362.38) C 62.97, H 3.06, N 15.46. Found C 
63.02, H 3.45, N 15.55. 
 
3-((6-(Pyridin-4-yl)imidazo[2,1-b]thiazol-5-yl)methylene)-1,3-dihydro-2H-benzo[g]indol-2-one 
(25). Red solid; 77% yield; E/Z 28/72; mp >320 °C. IR cm-1 1704, 1603, 1182, 1000. 1H NMR 
(DMSO-d6, 400 MHz) 7.40 (1H, d, th, J=4.5 Hz), 7.53 (2H, t, ind, J=7.2 Hz), 7.58 (1H, d, ind, 
J=8.8 Hz), 7.71 (1H, d, th, J=4.5 Hz), 7.74 (2H, dd, py, J=7.2, 0.8 Hz), 7.92 (1H, m, ind), 7.97 
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(1H, d, ind, J=8.8 Hz), 7.98 (1H, s, CH), 8.14 (1H, m, ind), 8.65 (2H, dd, py, J=7.2, 0.8 Hz), 11.37 
(1H, s, NH). Elemental analysis calcd (%) for C23H14N4OS (MW 394.45) C 70.03, H 3.58, N 
14.20. Found C 70.24, H 3.64, N 14.32. 
 
(E)-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (26). Yellow 
orange solid; 64% yield; mp 110-112 °C. IR cm-1 3550-3175, 1690, 1614. 1H NMR (DMSO-d6, 
400 MHz) 2.43 (3H, d, CH3, J=1.3 Hz), 4.01 (3H, s, O-CH3), 6.84 (1H, d, ind-4/7, J=7.6 Hz), 
6.97 (2H, m, ind), 7.15 (1H, t, ind-5/6, J=7.6 Hz), 7.49 (1H, s, CH), 7.85 (1H, q, th, J=1.3 Hz), 
10.45 (1H, s, NH). 13C NMR (DMSO-d6, 100 MHz)  13.3, 56.2, 105.6, 109.0, 117.7, 117.7, 
119.4, 120.6, 122.1, 124.6, 125.4, 127.7, 141.7, 147.0, 159.4, 169.2. Elemental analysis calcd (%) 
for C16H13N3O2S (MW 311.36) C 61.72, H 4.21, N 13.50. Found C 61.80, H 4.28, N 13.54. 
 
3-((6-Methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)-1-methylindolin-2-one (27). 
Yellow solid; 73% yield; E/Z 52/48; mp 140-143 °C. IR cm-1 1680, 1603, 1096, 1009. 1H NMR 
(DMSO-d6, 400 MHz) 2.43 (3H, s, CH3), 3.22 (3H, s, N-CH3), 4.01 (3H, s, O-CH3), 7.01 (2H, 
m, ind), 7.23 (1H, m, ind), 7.58 (1H, s, CHO), 7.62 (1H, m, ind), 7.84 (1H, s, th). Elemental 
analysis calcd (%) for C17H15N3O2S (MW 325.39) C 62.75, H 4.65, N 12.91. Found C 62.79, H 
4.61, N 11.98 
 
(E)-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)-1-phenylindolin-2-one (28). 
Orange solid; 60% yield; mp 100-106 °C. IR cm-1 1685, 1603, 1091, 1009. 1H NMR (DMSO-d6, 
400 MHz) 2.44 (3H, s, CH3), 4.05 (3H, s, O-CH3), 6.78 (1H, d, ind, J=7.4 Hz), 7.13 (3H, m), 
7.48 (3H, d, 1Hind J=7.4 Hz+2Har), 7.57 (2H, d, ar, J=6.6 Hz), 7.70 (1H, s, CH), 7.93 (1H, s, th). 
Elemental analysis calcd (%) for C22H17N3O2S (MW 387.46) C 68.20, H 4.42, N 10.85. Found C 
68.34, H 4.52, N 10.91. 
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(E)-5-methoxy-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (29). 
Red orange solid; 75% yield; mp 128-130 °C. IR cm-1 1698, 1615, 1272, 1213. 1H NMR (DMSO-
d6, 400 MHz) 2.43 (3H, s, CH3), 3.66 (3H, s, O-CH3), 4.02 (3H, s, O-CH3), 6.64 (1H, s, ind), 
6.73 (2H, s, ind), 7.49 (1H, s, CH), 7.88 (1H, s, th), 10.26 (1H, s, NH). 13C NMR (DMSO-d6, 100 
MHz)  13.2, 55.4, 56.4, 105.6, 109.2, 110.7, 113.6, 117.6, 117.8, 119.7, 122.9, 125.5, 135.6, 
147.1, 154.1, 159.4, 169.3. Elemental analysis calcd (%) for C17H15N3O3S (mw 341.39) C 59.81, 
H 4.43, N 12.31. Found C 59.90, H 4.51, N 12.38. 
 
(E)-5-methoxy-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)-6-methylindolin-2-
one (30). Red solid; 56% yield; mp 250-253 °C. IR cm-1 1683, 1603, 1120, 898. 1H NMR (DMSO-
d6, 400 MHz) 2.16 (3H, s, CH3), 2.43 (3H, s, CH3), 3.67 (3H, s, O-CH3), 4.03 (3H, s, O-CH3), 
6.65 (2H, s, ind), 7.41 (1H, s, CH), 7.82 (1H, s, th), 10.20 (1H, s, NH). 13C NMR (DMSO-d6, 100 
MHz)  13.2, 16.5, 55.4, 56.4, 105.5, 108.1, 111.1, 116.5, 117.6, 120.1, 120.3, 125.4, 125.7, 135.5, 
146.7, 151.9, 159.2, 169.5. Elemental analysis calcd (%) for C18H17N3O3S (MW 355.41) C 60.83, 
H 4.82, N 11.82. Found C 6091, H 4.92, N 11.89. 
 
(E)-5-hydroxy-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (31). 
Red orange solid; 63% yield; mp 277-278 °C. IR cm-1 3346, 1663, 1583, 1521. 1H NMR (DMSO-
d6, 400 MHz) 3.41 (3H, s, CH3), 4.01 (3H, s, O-CH3), 6.55 (2H, m, ind), 6.65 (1H, m, ind), 7.43 
(1H, s, CH), 7.81 (1H, s, th), 8.80 (1H, s, OH), 10.10 (1H, s, NH). 13C NMR (DMSO-d6, 100 MHz) 
13.3, 56.2, 105.4, 109.1, 112.3, 114.1, 117.4, 117.5, 120.6, 122.9, 125.4, 134.2, 146.7, 151.8, 
159.3, 169.2. Elemental analysis calcd (%) for C16H13N3O3S (MW 327.36) C 58.71, H 4.00, N 
12.84. Found C 58.80, H 4.08, N 12.79. 
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(E)-5-hydroxy-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)-6-methylindolin-2-
one (32). Red solid; 29% yield; mp 175-177 °C. IR cm-1 1670, 1603, 1532, 1017. 1H NMR 
(DMSO-d6, 400 MHz) 2.11 (3H, s, CH3), 2.42 (3H, s, CH3), 4.02 (3H, s, O-CH3), 6.53 (1H, s, 
ind), 6.56 (1H, s, ind), 7.35 (1H, s, CH), 7.77 (1H, s, th), 8.73 (1H, s, OH) 10.04 (1H, s, NH). 
Elemental analysis calcd (%) for C17H15N3O3S (MW 341.39) C 59.81, H 4.43, N 12.31. Found C 
59.88, H 4.48, N 12.29. 
 
(E)-4,7-dimethoxy-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(33). Brown solid; 56% yield; mp 193-195 °C. IR cm-1 1690, 1585, 1261, 1003. 1H NMR (DMSO-
d6, 400 MHz) 2.43 (3H, s, CH3), 3.78 (3H, s, O-CH3), 3.85 (3H, s, O-CH3), 4.01 (3H, s, O-CH3), 
6.55 (1H, d, ind, J=9 Hz), 6.81 (1H, d, ind, J=9 Hz), 7.38 (1H, s, th), 7.81 (1H, s, CH), 10.53 (1H, 
s, NH). Elemental analysis calcd (%) for C18H17N3O4S (MW 371.41) C 58.21, H 4.61, N 11.31. 
Found C 58.32, H 4.67, N 11.39. 
 
(E)-4,5,6-trimethoxy-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one 
(34). Red solid; 30% yield; mp 270-272 °C. IR cm-1 1680, 1578, 1291, 1091. 1H NMR (DMSO-
d6, 400 MHz) 2.44 (3H, s, CH3), 3.71 (3H, s, O-CH3), 3.81 (3H, s, O-CH3), 3.91 (3H, s, O-CH3), 
4.01 (3H, s, O-CH3), 6.32 (1H, s, ind), 7.42 (1H, s, th), 7.64 (1H, s, CH), 10.36 (1H, s, NH). ). 13C 
NMR (DMSO-d6, 100 MHz)  13.3, 56.1, 56.5, 60.0, 60.8, 90.7, 106.5, 108.7, 116.6, 117.5, 121.7, 
122.2, 135.9, 136.5, 147.1, 148.5, 153.4, 161.2, 167.4. (Elemental analysis calcd (%) for 
C19H19N3O5S (MW 401.44) C 56.85, H 4.77, N 10.47. Found C 56.93, H 4.89, N 10.43. 
 
(E)-5-chloro-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (35). 
Yellow solid; 47% yield; mp 270-275 °C. IR cm-1 1690, 1609, 1153, 717. 1H NMR (DMSO-d6, 
400 MHz) 2.44 (3H, s, CH3), 4.06 (3H, s, O-CH3), 6.83 (1H, d, ind-6/7, J=8.0 Hz), 6.99 (1H, s, 
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ind), 7.17 (1H, d, ind-6/7, J=8.0 Hz), 7.59 (1H, s, CH), 7.98 (1H, s, th), 10.57 (1H, s, NH). 
Elemental analysis calcd (%) for C16H12ClN3O2S (MW 345.80) C 55.57, H 3.50, N 12.15. Found 
C 55.62, H 3.56, N 12.12. 
 
4,7-Dichloro-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)indolin-2-one (36). 
Yellow solid; 52% yield; E/Z 68/32; mp 280-283 °C. IR cm-1 1696, 1588, 1153, 1081. 1H NMR 
(DMSO-d6, 400 MHz) 2.50 (3H, s, CH3), 4.06 (3H, s, O-CH3), 7.01 (1H, d, ind-5/6, J=9.2 Hz), 
7.21 (1H, d, ind-5/6, J=9.2 Hz), 7.46 (1H, s, CH), 8.21 (1H, s, th), 11.13 (1H, s, NH). Elemental 
analysis calcd (%) for C16H11Cl2N3O2S (MW 380.24) C 50.54, H 2.92, N 11.05. Found C 50.62, 
H 2.95, N 10.99. 
 
(E)-3-((6-methoxy-2-methylimidazo[2,1-b]thiazol-5-yl)methylene)-1,3-dihydro-2H-
benzo[g]indol-2-one (37). Dark red solid; 72% yield; mp 279-280 °C. IR cm-1 1675, 1598, 1514, 
1174. 1H NMR (DMSO-d6, 400 MHz) 2.43 (3H, s, CH3), 4.01 (3H, s, O-CH3), 7.27 (1H, d, ind, 
J=8.4 Hz), 7.48 (3H, m), 7.57 (1H, s, CH), 7.87 (2H, m), 8.12 (1H, m), 11.23 (1H, s, NH). ). 13C 
NMR (DMSO-d6, 100 MHz)  13.3, 56.2, 105.9, 116.9, 117.6, 117.9, 118.9, 119.7, 121.1, 122.2, 
122.3, 125.5, 126.1, 128.2, 132.7, 138.1, 147.1, 159.7, 171.1. Elemental analysis calcd (%) for 
C20H15N3O2S (MW 361.42) C 66.47, H 4.18, N 11.63. Found C 66.64, H 4.23, N 11.73.
 
(E)-3-((6-methyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (38). Red orange 
solid; 74% yield; mp 238-240 °C. IR cm-1 3417, 1696, 1600, 1206. 1H NMR (DMSO-d6, 400 MHz) 
2.02 (3H, s, CH3), 6.45 (1H, d, ind, J=7.2 Hz), 6.52 (1H, t, ind, J=7.2, 0.8 Hz), 6.78 (1H, d, ind, 
J=7.2 Hz), 7.09 (1H, t, ind, J=7.2, 0.8 Hz), 7.26 (1H, d, th, J=4.4 Hz), 7.48 (1H, d, th, J=4.4 Hz), 
7.57 (1H, s, CH), 7.87 (1H, d, th, J=4.4 Hz), 7.88 (1H, d, th, J=4.4 Hz), 10.54 (1H, s, NH). ). 13C 
NMR (DMSO-d6, 100 MHz) : 15.0, 109.4, 112.5, 114.6, 117.1, 118.8, 118.9, 119.6, 120.3, 120.4, 
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120.6, 123.1, 125.2, 129.5, 138.8, 142.4, 142.7. Elemental analysis calcd (%) for C20H13N5OS2 
(MW 403.48) C 59.54, H 3.25, N 17.36. Found C 59.63, H 3.19, N 17.43.
 
5-Methoxy-3-((6-methyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (39). Red 
solid; 15% yield; E/Z 90/10; mp 200-210 °C. IR cm-1 3114, 1690, 1608, 1204. 1H NMR (DMSO-
d6, 400 MHz) 2.14 (3H, s, CH3), 3.71 (3H, s, O-CH3), 6.72 (2H, m, ind), 7.30 (1H, d, th, J=4.5 
Hz), 7.38 (1H, d, th, J=4.5 Hz), 7.43 (1H, m, ind), 7.57 (1H, s, CH), 7.65 (1H, d, th, J=4.2 Hz), 
7.99 (1H, d, th, J=4.2 Hz), 10.40 (1H, s, NH). Elemental analysis calcd (%) for C21H15N5O2S2 
(MW 433.50) C 58.18, H 3.49, N 16.16. Found C 58.24, H 3.52, N 16.20. 
 
5-Chloro-3-((6-methyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (40). Red 
orange solid; 20% yield; E/Z 77/23; mp 200-205 °C. IR cm-1 1706, 1614, 1204, 897. 1H NMR 
(DMSO-d6, 400 MHz) 1.95 (3H, s, CH3), 6.28 (1H, d, ind-4, J=2.1 Hz), 6.73 (1H, d, ind-7, 
J=8.0 Hz), 7.07 (1H, dd, ind-6, J=8.0, 2.1 Hz), 7.25 (1H, d, th, J=4.4 Hz), 7.51 (1H, d, th, J=4.4 
Hz), 7.82 (1H, s, CH), 7.86 (1H, d, th, J=4.4 Hz), 8.18 (1H, d, th, J=4.4 Hz), 10.64 (1H, s, NH). 
Elemental analysis calcd (%) for C20H12ClN5OS2 (MW 437.92) C 54.85, H 2.76, N 15.99. Found 
C 54.89, H 2.77, N 16.03. 
 
6-Chloro-3-((6-methyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (41). Yellow 
orange solid; 21% yield; E/Z 68/32; mp 180-190 °C. IR cm-1 1706, 1619, 1153, 1071. 1H NMR 
(DMSO-d6, 400 MHz) 2.03 (3H, s, CH3), 6.42 (1H, d, ind-4, J=8.2 Hz), 6.52 (1H, dd, ind-5, 
J=8.2, 2.0 Hz), 6.79 (1H, d, ind-7, J=2.0 Hz), 7.26 (1H, d, th, J=4.5 Hz), 7.50 (1H, d, th, J=4.5 
Hz), 7.64 (1H, s, CH), 7.83 (1H, d, th, J=4.5 Hz), 7.95 (1H, d, th, J=4.5 Hz), 10.71 (1H, s, NH). 
Elemental analysis calcd (%) for C20H12ClN5OS2 (MW 437.92) C 54.85, H 2.76, N 15.99. Found 
C 5489, H 2.81, N 16.03. 
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3-((6-Methyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-1,3-dihydro-2H-benzo[g]indol-2-
one (42). Orange solid; 20% yield; E/Z 65/35; mp 240-245 °C. IR cm-1 1685, 1609, 1250, 810. 1H 
NMR (DMSO-d6, 400 MHz) 2.02 (3H, s, CH3), 6.69 (1H, d, ind, J=8.4 Hz), 7.02 (1H, d, ind, 
J=8.4 Hz), 7.28 (1H, d, th, J=4.4 Hz), 7.48 (1H, d, th, J=4.0 Hz), 7.50 (2H, m, ind), 7.65 (1H, s, 
CH), 7, 75 (1H, m, ind), 7.94 (1H, d, th, J=4.4 Hz), 7.98 (1H, d, th, J=4.0 Hz), 8.08 (1H, d, ind, 
J=8.0 Hz), 11.33 (1H, s, NH). Elemental analysis calcd (%) for C24H15N5OS2 (MW 453.54) C 
63.56, H 3.33, N 15.44. Found C 63.58, H 3.41, N 15.51. 
 
(E)-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-1-methylindolin-2-one 
(43). Yellow orange solid; 32% yield; mp 194-196 °C. IR cm-1 1698, 1610, 1163, 1086. 1H NMR 
(DMSO-d6, 400 MHz) 1.99 (3H, s, CH3), 2.44 (3H, s, CH3), 3.21 (3H, s, N-CH3), 6.51 (1H, d, 
ind-4/7, J=7.6 Hz), 6.60 (1H, t, ind-5/6, J=7.6 Hz), 6.96 (1H, d, ind-4/7, J=7.6 Hz), 7.18 (1H, t, 
ind-5/6, J=7.6 Hz), 7.25 (1H, d, th, J=4.4 Hz) 7.60 (1H, s, CH), 7.68 (1H, s, th), 7.87 (1H, d, th, 
J=4.4 Hz). Elemental analysis calcd (%) for C22H17N5OS2 (MW 431.53) C 61.23, H 3.97, N 16.23. 
Found C 61.31, H 4.01, N 16.33. 
 
3-((2',6-Dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-1-phenylindolin-2-one (44). 
Orange solid; 37% yield; E/Z 79/21; mp 150-155 °C. IR cm-1 1704, 1598, 1183, 1091. 1H NMR 
(DMSO-d6, 400 MHz) 2.09 (3H, s, CH3), 2.47 (3H, q, CH3, J=1.6 Hz), 6.60 (1H, d, ind, J=7.6 
Hz), 6.65 (1H, t, ind, J=7.6 Hz), 6.70 (1H, d, ind, J=7.6 Hz), 7.12 (1H, t, ind, J=7.6 Hz), 7.27 (1H, 
d, th, J=4.4 Hz), 7.49 (3H, m, ar), 7.59 (2H, m, ar), 7.73 (1H, s, CH), 7.80 (1H, d, th, J=1.6 Hz), 
7.85 (1H, d, th, J=4.4 Hz). Elemental analysis calcd (%) for C27H19N5OS2 (MW 493.60) C 65.70, 
H 3.88, N 14.19. Found C 65.75, H 3.91, N 14.22. 
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3-((2',6-Dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-5-methoxyindolin-2-one (45). 
Red orange solid; 43% yield; E/Z 74/26; mp 195-197 °C. IR cm-1 1701, 1296, 1189, 1030. 1H 
NMR (DMSO-d6, 400 MHz) 1.95 (3H, s, CH3), 2.47 (3H, q, CH3, J=1.2 Hz), 3.30 (3H, s, 
OCH3), 6.04 (1H, s, ind), 6.70 (2H, s, ind), 7.25 (1H, d, th, J=4.4 Hz), 7.55 (1H, s, CH), 7.76 (1H, 
d, th, J=1.2 Hz), 7.94 (1H, d, th, J=4.4 Hz), 10.37 (1H, s, NH). Elemental analysis calcd (%) for 
C22H17N5O2S2 (MW 447.53) C 59.04, H 3.83, N 15.65. Found C 58.99, H 3.85, N 15.67. 
 
(E)-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-5-methoxy-1-
methylindolin-2-one (46). Red solid; 46% yield; mp 255-259 °C. IR cm-1 1693, 1629, 1273, 974. 
1H NMR (DMSO-d6, 400 MHz) 1.93 (3H, s, CH3), 2.46 (3H, s, CH3), 3.19 (3H, s, N-CH3), 3.42 
(3H, s, O-CH3), 6.09 (1H, d, ind-4, J=2.3 Hz), 6.79 (1H, dd, ind-6, J=8.5, 2.3 Hz), 6.89 (1H, d, 
ind-7, J=8.5 Hz), 7.26 (1H, d, th, J=4.4 Hz), 7.63 (1H, s, CH), 7.75 (1H, s, th), 7.95 (1H, d, th, 
J=4.4 Hz). Elemental analysis calcd (%) for C23H19N5O2S2 (MW 461.56) C 59.85, H 4.15, N 15.17. 
Found C 59.91, H 4.21, N 15.20. 
 
(E)-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-5-hydroxyindolin-2-one 
(47). Red solid; 38% yield; mp >315 °C. IR cm-1 3500, 1680, 1603, 1204. 1H NMR (DMSO-d6, 
400 MHz) 2.05 (3H, s, CH3), 2.45 (3H, q, CH3, J=1.4 Hz), 6.02 (1H, d, ind-4, J=2.0 Hz), 6.55 
(1H, dd, ind-6, J=8.5, 2.0 Hz), 6.62 (1H, d, ind-7, J=8.5 Hz), 7.24 (1H, d, th, J=4.5 Hz), 7.38 (1H, 
s, CH), 7.54 (1H, d, th, J=1.4 Hz), 7.87 (1H, d, th, J=4.5), 8.74 (1H, s, OH), 10.28 (1H, s, NH). 
Elemental analysis calcd (%) for C21H15N5O2S2 (MW 433.50) C 58.18, H 3.49, N 16.16. Found C 
58.22, H 3.52, N 16.20. 
 
(E)-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-5-fluoroindolin-2-one (48). 
Red solid; 35% yield; mp 255-258 °C. IR cm-1 3560, 1689, 1602, 1250. 1H NMR (DMSO-d6, 400 
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MHz) 1.99 (3H, s, CH3), 2.47 (3H, q, CH3, J=1.6 Hz), 6.12 (1H, dd, ind-4, J=9.0, 2.6 Hz), 6.70 
(1H, dd, ind-7, J=8.6, 4.4 Hz), 6.88 (1H, td, ind-6, J=9.0, 2.6 Hz), 7.23 (1H, d, th, J=4.4 Hz), 7.68 
(1H, s, CH), 7.79 (1H, d, th, J=4.4 Hz), 7.90 (1H, d, th, J=1.6 Hz), 10.53 (1H, s, NH). Elemental 
analysis calcd (%) for C21H14FN5OS2 (MW 435.50) C 57.92, H 3.24, N 16.08. Found C 56.89, H 
3.30, N 16.13. 
 
5-Chloro-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (49). 
Dark red solid; 18% yield; E/Z 78/22; mp 200-202 °C. IR cm-1 1702, 1610, 1204, 1102. 1H NMR 
(DMSO-d6, 400 MHz) 1.93 (3H, s, CH3), 2.48 (3H, q, CH3, J=1.6 Hz), 6.26 (1H, d, ind, J=2.2 
Hz), 6.73 (1H, d, ind, J=8.4 Hz), 7.06 (1H, dd, ind, J=8.4, 2.2 Hz), 7.24 (1H, d, th, J=4.4 Hz), 7.76 
(1H, s, CH), 7.85 (1H, d, th, J=4.4 Hz), 8.00 (1H, d, th, J=1.6 Hz), 10.62 (1H, s, NH). Elemental 
analysis calcd (%) for C21H14ClN5OS2 (MW 451.95) C 55.81, H 3.12, N 15.50. Found C 55.83, H 
3.15, N 15.54. 
 
(E)-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)-4-fluoroindolin-2-one (50). 
Red solid; 43% yield; mp 268-270 °C. IR cm-1 3575, 1688, 1603, 1250. 1H NMR (DMSO-d6, 400 
MHz) 2.01 (3H, s, CH3), 2.45 (3H, q, CH3, J=1.2 Hz), 6.28 (1H, td, ind-6, J=8.4, 2.4 Hz), 6.44 
(1H, dd, ind-5, J=8.4, 5.6 Hz), 6.59 (1H, dd, ind-7, J=9.4, 2.4 Hz), 7.24 (1H, d, th, J=4.4 Hz), 7.53 
(1H, s, CH), 7.75 (1H, d, th, J=1.2 Hz), 7.81 (1H, d, th, J=4.4 Hz), 10.63 (1H, broad, NH). 
Elemental analysis calcd (%) for C21H14FN5OS2 (MW 435.50) C 57.92, H 3.24, N 16.08, Found 
C 57.89, H 3.26, N 16.11. 
 
(E)-4-chloro-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (51). 
Red solid; 44% yield; mp 217-220 °C. IR cm-1 1701, 1680, 1578, 881. 1H NMR (DMSO-d6, 400 
MHz) 2.19 (3H, s, CH3), 2.65 (3H, s, CH3), 6.91 (1H, d, ind-5/7, J=8 Hz), 7.04 (1H, d, ind-5/7, 
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J=8.0 Hz),7.25 (1H, t, ind-6, J=8.0 Hz), 7.31 (1H, d, th, J=4.4 Hz), 7.50 (1H, s, th), 7.93 (1H, s, 
CH), 8.03 (1H, d, th, J=4.4 Hz), 10.90 (1H, s, NH). Elemental analysis calcd (%) for 
C21H14ClN5OS2 (MW 451.95) C 55.81, H 3.12, N 15.50. Found 55.79, H 3.10, N 15.48. 
 
(E)-6-chloro-3-((2',6-dimethyl-[5,6'-biimidazo[2,1-b]thiazol]-5'-yl)methylene)indolin-2-one (52). 
Red solid; 33% yield; mp 279-281 °C. IR cm-1 1696, 1609, 1071, 979. 1H NMR (DMSO-d6, 400 
MHz) 2.01 (3H, s, CH3), 2.46 (3H, s, CH3), 6.41 (1H, d, ind-4, J=8.3 Hz), 6.52 (1H, dd, ind-5, 
J=8.3, 1.8 Hz), 6.78 (1H, d, ind-7, J=1.8 Hz), 7.25 (1H, d, th, J=4.4 Hz), 7.59 (1H, s, CH), 7.77 
(1H, s, th), 7.81 (1H, d, th, J=4.4 Hz), 10.69 (1H, s, NH). Elemental analysis calcd (%) for 
C21H14ClN5OS2 (MW 451.95) C 55.81, H 3.12, N 15.50. Found C 55.79, H 3.10, N 15.47. 
 
4.1.2. Synthesis of 6-methoxy-2-methylimidazo[2,1-b]thiazole-5-carbaldehyde (1c) 
6-Chloro-2-methylimidazo[2,1-b]thiazole-5-carbaldehyde (10 mmol) was dissolved in methanol 
(100 mL) and treated with CH3ONa (50 mmol). The reaction mixture was kept for 3 h at room 
temperature and under reflux for 5 h. After cooling, methanol was evaporated under reduced 
pressure, and the residue was added to water. The resulting precipitate was collected by filtration 
and crystallized from methanol. 
Orange solid; 65% yield; mp 119-121 °C. IR (cm-1): 1639, 1547, 1107, 1004. 1H NMR (DMSO-
d6, 400 MHz)  2.45 (3H, d, CH3, J=1.5 Hz), 4.02 (3H, s, CH3), 8.03 (1H, q, th, J=1.5 Hz), 9.46 
(1H, s, CH). Anal. Calcd for C8H8N2O2S (MW 196.22) C 48.97, H 4.11, N 14.28. Found C 49.01, 
H 4.10, N 14.37. 
 
4.1.3. Synthesis of imidazo[2,1-b]thiazoles 57d,e 
2-Aminothiazole or 5-methylthiazol-2-amine 54d,e (20 mmol) was dissolved in 100 mL of acetone 
and treated with one equivalent of 2-bromo-1-(6-methylimidazo[2,1-b]thiazol-5-yl)ethan-1-one 
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55. The reaction mixture was refluxed for 9-10 h (reaction followed by TLC), and the resulting 
salt (56d,e) was separated by filtration and used without further purification (C=O absorption was 
confirmed around 1700 cm-1) in the subsequent step. It was refluxed for 1 h with 200 mL of 2 N 
HCl, and, before complete cooling, the solution was cautiously basified by dropwise addition of 
15% NH4OH. The resulting base was collected by filtration and crystallized from 
acetone/petroleum ether. 
 
6-Methyl-5,6'-biimidazo[2,1-b]thiazole (57d). Red solid; yield 50%; mp 169-171 °C; IR (cm-1): 
1595, 1020, 861, 723; 1H NMR (DMSO-d6, 400 MHz)  2.41 (3H, s, CH3), 7.25 (1H, d, th, J=4.4 
Hz), 7.31 (1H, d, th, J=4.4 Hz), 7.95 (1H, d, th, J=4.4 Hz), 8.02 (1H, s, im), 8.29 (1H, d, th, J=4.4 
Hz). Anal. Calcd for C11H8N4S2 (MW 260.33): C, 50.75; H, 3.10; N, 21.52. Found: C, 50.78; H, 
3.15; N, 21.50. 
 
2',6-Dimethyl-5,6'-biimidazo[2,1-b]thiazole (57e). Red solid; yield 30%; mp 173-175°C; IR (cm-
1): 1598, 1189, 835, 799; 1H NMR (DMSO-d6, 400 MHz)  2.40 (6H, s, 2xCH3), 7.23 (1H, d, th, 
J=4.4 Hz), 7.70 (1H, s, th), 7.92 (1H, s, im), 8.28 (1H, d, th, J=4.4 Hz). Anal. Calcd for C12H10N4S2 
(MW 274.36): C, 52.53; H, 3.67; N, 20.42. Found: C, 52.49; H, 3.71; N, 20.38. 
 
4.1.4. Synthesis of aldehydes 1d,e 
The Vilsmeier reagent was prepared at 0-5 °C by dropping POCl3 (54 mmol) into a stirred solution 
of DMF (65 mmol) in CHCl3 (5 mL). The appropriate condensed imidazole 57d,e (5 mmol) was 
suspended in CHCl3 (20 mL). The mixture thus obtained was dropped into the Vilsmeier reagent 
while maintaining stirring and cooling. The reaction mixture was kept for 3 h at room temperature 
and under reflux for 4 h. Chloroform was removed under reduced pressure and the resulting oil 
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was poured onto ice. The solution was basified by addition of NH4OH, and the crude aldehydes 
1d,e were crystallized from ethanol. 
 
6-Methyl-[5,6'-biimidazo[2,1-b]thiazole]-5'-carbaldehyde (1d). Red solid; yield 80%; mp 240-
242°C; IR (cm-1): 1658, 1149, 1020, 721; 1H NMR (DMSO-d6, 400 MHz)  2.41 (3H, s, CH3), 
7.31 (1H, d, th, J=4.4 Hz), 7.61 (1H, d, th, J=4.4 Hz), 7.97 (1H, d, th, J=4.4 Hz), 8.41 (1H, d, th, 
J=4.4 Hz), 9.69 (1H, s, CHO). Anal. Calcd for C12H8N4OS2 (MW 288.34): C, 49.99; H, 2.80; N, 
19.43. Found: C, 49.78; H, 2.85; N, 19.48. 
 
2',6-Dimethyl-[5,6'-biimidazo[2,1-b]thiazole]-5'-carbaldehyde (1e). Red solid; yield 75%; mp 
282-284 °C; IR (cm-1): 1643, 1152, 1020, 723; 1H NMR (DMSO-d6, 400 MHz)  2.55 (6H, s, 
2xCH3), 6.86 (1H, d, th, J=4.4 Hz), 7.87 (1H, d, th, J=4.4 Hz), 8.11 (1H, s, th), 8.71 (1H, s, CHO). 
Anal. Calcd for C13H10N4OS2 (MW 302.37): C, 51.64; H, 3.33; N, 18.53; O, 5.29; S, 21.21. Found: 
C, 51.60; H, 3.35; N, 18.53. 
 
4.2. Biology 
4.2.1. Cell-Based Screening Assay  
 The NCI screening process [38] occurs in two stages, beginning with the evaluation of all 
compounds against the 60 cell lines at 10-5 M. Compounds exhibiting significant growth inhibition 
are subsequently evaluated against the 60 cell lines at five concentration levels according to 
standard procedures (http://dtp.nci.nih.gov/branches/btb/ivclsp.html). In both cases, the exposure 
time is 48 h.   
 
4.2.2. Cell growth conditions and antiproliferative assay 
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 PBL from healthy donors were obtained by separation on a Lymphoprep (Fresenius KABI 
Norge AS) gradient. After extensive washing, cells were resuspended (1.0 x 106 cells/mL) in 
RPMI-1640 with 10% fetal bovine serum and incubated overnight.  
For cytotoxicity evaluations in proliferating PBL cultures, non-adherent cells were resuspended at 
5 x 105 cells/mL in growth medium, containing 2.5 µg/mL PHA (Irvine Scientific). Different 
concentrations of the test compounds were added, and viability was determined 72 h later by the 
MTT test. For cytotoxicity evaluations in resting PBL cultures, non-adherent cells were 
resuspended (5 x 105 cells/mL) and treated for 72 h with the test compounds. Cell viability was 
assayed by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test as previously 
described [32,33].   
 
4.2.3. Effects on tubulin polymerization and on colchicine binding to tubulin  
 To evaluate the effect of the compounds on tubulin assembly in vitro [25], varying 
concentrations of compounds were preincubated with 10 M bovine brain tubulin in glutamate 
buffer at 30 °C and then cooled to 0 °C. After addition of 0.4 mM GTP (final concentration), the 
mixtures were transferred to 0 °C cuvettes in a recording spectrophotometer equipped with an 
electronic temperature controller and warmed to 30 °C. Tubulin assembly was followed 
turbidimetrically at 350 nm. The IC50 was defined as the compound concentration that inhibited 
the extent of assembly by 50% after a 20 min incubation. The ability of the test compounds to 
inhibit colchicine binding to tubulin was measured as described [39], except that the reaction 
mixtures contained 1 M tubulin, 5 M [3H]colchicine and  5 or 50 M test compound. 
 
4.2.4. Flow cytometric analysis of cell cycle distribution 
 5 × 105 HeLa cells were treated with different concentrations of the test compounds for 24 
h. After the incubation period, the cells were collected, centrifuged, and fixed with ice-cold ethanol 
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(70%). The cells were then treated with lysis buffer containing RNase A and 0.1% Triton X-100 
and then stained with PI. Samples were analyzed on a Cytomic FC500 flow cytometer (Beckman 
Coulter). DNA histograms were analyzed using MultiCycle for Windows (Phoenix Flow 
Systems). 
 
4.2.5. Mitotic index 
 K562 human leukemia cells were grown in RPMI 1640 medium supplemented with 5% 
fetal bovine serum for 16 h in a 5% CO2, humidified atmosphere at 37 °C. Cells were harvested 
by centrifugation, smeared onto a glass slide, fixed with ethanol, stained with Giemsa, and the 
proportion of cells with condensed chromosomes was determined. Without compounds the mitotic 
index was 3%. 
 
4.2.6. Apoptosis assay 
 Cell death was determined by flow cytometry of cells double stained with annexin V/FITC 
and PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to measure the surface 
exposure of phosphatidyl serine on apoptotic cells according to the manufacturer’s instructions 
(Annexin-V Fluos, Roche Diagnostics). 
 
4.2.6. Western blot analysis  
 HeLa cells were incubated in the presence of the test compounds and, after different times, 
were collected, centrifuged, and washed two times with ice-cold phosphate-buffered saline (PBS). 
The pellet was then resuspended in lysis buffer. After the cells were lysed on ice for 30 min, lysates 
were centrifuged at 15000 x g at 4 °C for 10 min. The protein concentration in the supernatant was 
determined using the BCA protein assay reagents (Pierce, Italy). Equal amounts of protein (10 μg) 
were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Criterion Precast, 
BioRad, Italy) and transferred to a PVDF Hybond-P membrane (GE Healthcare). Membranes were 
 52 
 
52 
blocked with a bovine serum albumin solution (5% in Tween PBS 1X), the membranes being 
gently rotated overnight at 4 °C. Membranes were then incubated with primary antibodies against 
Bcl-2, Mcl-1, PARP, cdc25c, cyclin B, p-cdc2Tyr15, Cleaved caspase-9 (Asp330), Cleaved caspase-
3 (Asp175) (all from Cell Signaling), or β-actin (Sigma-Aldrich) for 2 h at room temperature. 
Membranes were next incubated with peroxidase labeled secondary antibodies for 60 min. All 
membranes were visualized using ECL Select (GE Healthcare), and images were acquired using 
an Uvitec-Alliance imaging system (Uvitec, Cambridge, UK). To ensure equal protein loading, 
each membrane was stripped and reprobed with anti-β-actin antibody. Densitometric analysis of 
western blot was performed by Image J software and the results were normalized to β-actin and 
represented as fold change respect to untreated controls.  
 
4.2.7. In vivo animal studies 
 Animal experiments were approved by our local animal ethics committee (OPBA, 
Organismo Preposto al Benessere degli Animali, Università degli Studi di Brescia, Italy) and were 
executed in accordance with national guidelines and regulations. Procedures involving animals 
and their care conformed with institutional guidelines that comply with national and international 
laws and policies (EEC Council Directive 86/609, OJ L 358, 12 December 1987) and with 
“ARRIVE” guidelines (Animals in Research Reporting In Vivo Experiments). Six weeks old 
C57BL/6 mice (Envigo) were injected subcutaneously into the dorsolateral flank with 2.5x105 
BL6-B16 murine melanoma cells in 200 µL-total volume of PBS. Six weeks old C57BL/6 female 
mice (Envigo) were injected subcutaneously into the dorsolateral flank with 2.5x105 E0771 murine 
breast cancer cells in 200 µL of PBS. When tumors were palpable, animals were treated 
intraperitoneally every other day with different doses of test compounds dissolved in 50 µL of 
DMSO. Tumors were measured in two dimensions, and tumor volume was calculated according 
to the formula V=(D x d2)/2, where D and d are the major and minor perpendicular tumor 
diameters, respectively.  
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Statistical analysis.  
Graphs and statistical analyses were performed using GraphPad Prism 7.05 software (GraphPad, 
La Jolla, CA). All data in histograms and plots represent the mean of at least three independent 
experiments ±standard error of the mean (SEM). Statistical significance was analysed using 
Student t test or ANOVA (one- or two-way) depending on the type of data. For multiple test 
comparison, Dunnett’s test were applied. Asterisks indicate a significant difference between the 
treated and the control group, unless otherwise specified; *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. 
 For tumor volume evaluation data were analyzed with a 2-way analysis of variance, and individual 
group comparisons were evaluated by the Bonferroni correction. 
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